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ZUSAMMENFASSUNG 
Obgleich bekannt ist, dass die Ausprägung zahlreicher neuropsychiatrischer Erkrankungen genetisch 
bedingt ist, sind die grundlegenden Mechanismen dieses Zusammenhangs noch weitestgehend 
unbekannt. Eine Methode, um Einblicke in die Genetik neuropsychiatrischer Erkrankungen zu 
erhalten, sind genomweite Assoziationsstudien (GWASs). Mit Hilfe dieser konnten bisher über 2.000 
Loci für genetische Risikofaktoren von Hirnerkrankungen identifiziert werden. Die Mehrheit dieser 
Loci befindet sich in nicht-codierenden DNA-Bereichen, was ihre funktionelle Erforschung erschwert. 
Die vorliegende Arbeit geht der Fragestellung nach, inwieweit regulatorische Sequenzvarianten, 
welche DNA-Methylierung und Genexpression beeinflussen, zur genetischen Disposition von 
neuropsychiatrischen Erkrankungen beitragen. 
Meine Studie nutzt einen integrativen Ansatz der funktionellen Genomik, um epigenetische 
Regulationen im hippocampalen Hirngewebe bei Patienten mit pharmakoresistenter mesialer 
Temporallappenepilepsie zu untersuchen. Hierzu wurden SNP-Genotypen mit genomweiter CpG-
Methylierung und mRNA Genexpression korreliert. Die daraus resultierenden »genomweiten 
Landkarten« von quantitativen Methylierungs Trait Loci (meQTLs) und quantitativen Expressions 
Trait Loci (eQTLs) wurden zur Lokalisation von regulatorischen SNPs (rSNPs) verwendet die in 
Zusammenhang mit einigen Hirnerkrankungen stehen (488 GWAS Katalog Einträge, P < 5,0 x 10-8). 
Die vorliegende Arbeit stellt die erste meQTL Studie dar, welche den leistungsfähigen Human 
Methylation450 array auf Basis von frisch-gefrorenem menschlichem Hirngewebe verwendet. Mit 
Hilfe einer linearen Regressionsanalyse und unter Berücksichtigung einer Korrektur für die 
Gewebeheterogenität, wurden insgesamt 19.954 (8,5% der 362.000 CpGs) cis-regulierte meQTLs 
identifiziert. Dies entspricht einer Versechsfachung der bisher bekannten meQTLs aus postmortalem 
Hirngewebe. Eine signifikante Anreicherung der meQTLs in der 5´-regulatorischen Region vor den 
Genpromotoren (TSS201-1500; P = 7,7 x 10-61) spiegelt den funktionellen Einfluss dieser Region 
wider, welche Enhancer als auch Insulatoren beherbergt. Es hat sich gezeigt, dass einige der hoch 
signifikanten cis-meQTLs bekannte Kandidaten Gene für neurologische Entwicklungsstörungen 
beeinflussen (ADARB2, HDAC4, NAPRT1, MAD1L1, PTPRN2 und RIMBP2). Die Gewebespezifität 
wurde anhand einer weiteren meQTL-Analyse, unter Beibehaltung gleicher experimenteller 
Bedingungen, in Blutzellen von 496 deutsch stämmigen Kontrollproben ohne neuropsychiatrische 
Erkrankungen untersucht. 65% der im Hirngewebe identifizierten meQTLs konnten auch in Blutzellen 
wiedergefunden werden (Spearman Rank Koeffizient = 0,42). Diese nennenswerte Übereinstimmung 
eröffnet die Möglichkeit, epigenetische Biomarker für komplexe Hirnerkrankungen in einfach 
zugänglichem Gewebe auszuwählen. Die zusätzlich zur meQTL Analyse durchgeführte eQTL Analyse 
konnte unter den 31.000 mRNA-Sonden insgesamt 734 signifikant cis-wirkende eQTLs identifizieren. 
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In einer weiteren Analyse wurden CpG-Methylierung und Genexpression korreliert – diese stellt die 
erste systematische Untersuchung dieser Form in frisch-gefrorenem Hirngewebe dar. Hierbei wurden 
sowohl negative (73%) als auch positive (27%) Korrelationen beobachtet. Die stärksten negativen 
Korrelationen wurden bei dem Gen NAPRT1, welches die Nicotinat Phosphoribosyltransferase 
kodiert, beobachtet. Des Weiteren konnte bei den mit NAPRT1 assoziierten meQTLs und eQTLs eine 
genetische Beeinflussung durch ein und denselben SNP rs9657360 festgestellt werden. Die 
Korrelations-Ergebnisse kombiniert mit der genetischen Beeinflussung des SNPs zeigten auf, dass das 
minor C Allel eben dieses SNPs mit einer erhöhten Methylierung in der NAPRT1-Promoterregion und 
einer verminderten Genexpression assoziiert ist. Die Kombination aus einer tumorspezifischen 
Hypermethylierung einer in der Promoterregion gelegenen CpG island mit gleichzeitiger 
Verminderung der NAPRT1 Expression wurde ebenfalls in der Krebsforschung erkannt: NAPRT1 kann 
als prädiktiver Biomarker zur Therapie von Karzinomen mit NAMPT Inhibitoren eingesetzt werden. 
Durch den innovativen Ansatz, translationale Auswirkungen der epigenetischen Regulation der 
Genexpression in Kombination mit meQTLs und eQTLs zu testen, wurde zusätzliche eine genetische 
Determination erkannt. Diese ist von großer klinischer Bedeutung, da sie einen Ansatz zur Erfassung 
von Patienten erlaubt, die von der Gabe von NAMPT Inhibitoren profitieren können. 
Zusätzlich wurde eine Imprinting meQTL (imeQTL) Analyse durchgeführt, um das Potential der 
Kombination aus Imprinting  und Methylierung zu untersuchen. Zur Erfassung der imeQTLs wurde 
der Methylierungsstatus von 269 Individuen (auf Basis von Blutzellen), stratifiziert nach den elterlich 
inversen heterozygoten Genotypen, verglichen. Insgesamt konnten 177 CpGs an 31 genomischen 
Loci identifiziert werden, von denen 22 bisher unbekannte Imprinting Regionen darstellen. Die 
stärkste Auswirkung von Parent-of-Origin-Effekte auf Methylierung wurde in Regionen beobachtet, 
die Gene für neurologische Entwicklungsstörungen beherbergen, sowie im chromosomalen Segment 
3p21.1, welches eine GWAS Kandidaten Region für affektive Störungen ist. Positionelle Gene in 
Imprinting Regionen sind aussichtsreiche Kandidaten Gene aufgrund ihrer potentiell monoallelischen 
Genexpression. Hierdurch wird es möglich, potentiell rezessive Erkrankungsmutationen zu ermitteln. 
Die Enrichment Analysen von cis-meQTL assoziierten Genen ergab eine Überrepräsentation von 
Genen, die positionell im Bereich von GWAS Loci liegen (P = 5,8 x 10-4). Potentielle rSNPs wurden in 
der GWAS Kandidaten Region von 1q31.2 (RGS1) und von 3p21.1 (PRBM1) lokalisiert. Die allelische 
Veränderung von Transkriptionsfaktor-Bindungsstellen durch potentielle rSNPs führt zu quantitativen 
Änderungen der Gentranskription oder Spleißprozessen, welche wiederum zu pathogenen Verläufen 
von neuropsychiatrischen Erkrankungen beitragen. Die aus diesen Studien hervorgehende 
Datenbank von autosomalen meQTLs, imeQTLs und eQTLs in Hirngewebe stellt eine wertvolle Quelle 
dar, um rSNPs zu identifizieren und deren Beteiligung an Erkrankungsprozessen aufzuklären.  
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ABSTRACT 
Neuropsychiatric disorders have a strong genetic predisposition, but their genetic basis remains 
elusive. Genome-wide association studies (GWASs) have mapped more than 2,000 susceptibility loci 
that were shown to increase the risk of common brain disorders. However, the majority of these 
susceptibility loci reside in non-coding regions and their functional consequences are unknown. The 
present study addresses the question whether regulatory sequence variants, affecting DNA 
methylation and gene expression, may be causal susceptibility alleles. 
I used an integrative functional genomics approach to investigate epigenetic regulation phenomena 
in human hippocampal brain of 115 European patients with pharmacoresistant mesial temporal lobe 
epilepsy. High-density SNP genotypes were correlated with genome-wide quantitative CpG 
methylation and mRNA expression levels using the Human Methylation450 array (HM450) and the 
Human HT-12 v3 array. Subsequently, a genome-wide map of methylation quantitative trait loci 
(meQTLs) and expression quantitative trait loci (eQTLs) was used to dissect regulatory SNPs (rSNPs) 
that confer susceptibility to common brain disorders at 488 known GWAS hits (P < 5.0 x 10-8). 
This is the first meQTL study of brain tissue applying the high-density HM450 array in specimens of 
fresh frozen human brain tissue obtained by epilepsy surgery at large scale. Linear regression analysis 
of this study implementing a correction for cell-type heterogeneity, identified 19,954 (8.5% of 362k 
CpGs) cis-acting meQTLs at a false-discovery rate (FDR) of 5%, which is a six-fold increase compared 
to previous meQTL studies that all investigated postmortem brain tissue. Specifically, cis-meQTLs 
were strongly enriched upstream of the gene promoter region (TSS201-1500; P = 7.7 x 10-61), 
highlighting the functional impact of this 5´-regulatory region that harbors binding sites of enhancers 
and insulators. Some of the most significant cis-meQTLs affected high-ranking candidate genes 
(ADARB2, HDAC4, NAPRT1, MAD1L1, PTPRN2 and RIMBP2) for neurodevelopmental disorders. To 
explore tissue specifity, the same approach was repeated in an additional meQTL analysis of whole 
blood cells originating from 496 German population controls without neuropsychiatric disorders. 
Results show that 65% of the meQTLs in brain tissues were also present in whole blood cells 
(Spearman’s Rank coefficient = 0.42). The present database of cis-meQTLs in brain and blood cells 
provides a key to select accessible epigenetic biomarkers for brain disorders in whole blood cells. The 
performed eQTL study identified 734 out of 31k mRNA probes at which expression levels were 
significantly influenced by cis-acting SNPs (FDR < 5%). 
Apart from meQTL and eQTL analyses, additionally a CpG methylation to gene expression correlation 
analysis was performed. This represents the first systematic delineation of methylation-driven genes 
in fresh frozen brain tissue. Both inverse correlations (73%) and positive correlations (27%) were 
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observed, whereby the strongest inverse correlations were detected at NAPRT1, the gene encoding 
Nicotinate Phosphoribosyltransferase. Furthermore, the NAPRT1-associated meQTLs and eQTL were 
both genetically regulated by SNP rs9657360. The minor C allele of that very SNP was significantly 
associated with high methylation levels in the NAPRT1 promoter region and simultaneously 
associated with low gene expression of NAPRT1. Both, the tumor-specific hypermethylation of a 
promoter CpG island as well as loss of NAPRT1 expression have been previously proposed as 
predictive biomarkers for the therapy of carcinomas using NAMPT inhibitors. The additionally genetic 
risk constellation which has been identified by my approach – combining meQTLs and eQTLs to 
unravel the translational impact of epigenetic regulation of gene expression – is of high clinical 
relevance. It enables a diagnostically driven clinical strategy in tumorigenesis including the selection 
of patients which likely benefit from the administration of NAMPT inhibitors. 
To dissect imprinted meQTLs (imeQTLs) exhibiting differential methylation in a Parent-of-Origin 
(PofO) dependent manner, the CpG methylation states of blood cells in groups of 269 individuals 
stratified by parentally inverse heterozygous genotypes of nearby SNPs were compared. The imeQTL 
analysis revealed 177 CpGs at 31 genomic loci of which 22 were previously unknown. The strongest 
PofO effects were observed at loci harboring neurodevelopmental genes and on chromosome 
3p21.1, which is a GWAS candidate region for mood disorders. Genes at genomic loci that show 
imprinting effects are promising candidate genes because of their potentially monoallelic gene 
expression which may unmask recessive susceptibility alleles. 
Enrichment analyses of genes associated with cis-meQTLs revealed an overrepresentation of genes 
implicated in GWAS hits of brain disorders (P = 5.8 x 10-4). Potential rSNPs at the GWAS candidate loci 
1q31.2 (RGS1 gene locus) and 3p21.1 (PRBM1 gene locus) were identified. The allelic alteration of 
transcription factor binding sites by potential rSNPs is likely to result in changes of gene transcription 
or splicing processes which could contribute to pathogenic pathways underlying neuropsychiatric 
disorders. As exemplified in this thesis, the created database of autosomal meQTLs, imeQTLs and 
eQTLs in brain tissue provides a valuable resource to dissect rSNPs at GWAS hits and to decipher 
their functional effects.  
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1. INTRODUCTION 
1.1 Neuropsychiatric disorders 
Neuropsychiatric disorders such as epilepsy, schizophrenia, bipolar disorder, major depressive 
disorder, autism spectrum disorder, attention deficit-hyperactivity disorder and substance use 
disorders represent 13% of the global burden of diseases, surpassing cardiovascular disease and 
cancer (World Health Organization 2008; Collins et al. 2011). They cause enormous personal and 
social burdens (Collins et al. 2011; Labrie et al. 2012) and have a lifetime prevalence that ranges from 
0.1% for autism spectrum disorder to approximately 1% for schizophrenia and up to 24% for nicotine 
dependence (Sullivan et al. 2012). Family studies, including twin and adoption studies provide 
consistent evidence that genetic factors contribute to the risk of neuropsychiatric disorders (Kendler 
et al. 2005). These family studies assessed heritability estimates ranging from 37% for major 
depressive disorder to more than 80% for schizophrenia and bipolar disorder (Cardno et al. 1999; 
Sullivan et al. 2012) and show empirical evidence of a shared genetic etiology across neuropsychiatric 
disorders (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013). Overall, almost all 
neuropsychiatric traits display a complex genetic predisposition (Labrie et al. 2012; Gelernter 2015) 
and only a small fraction follows mendelian inheritance patterns (Lander & Schork 1994). There is no 
common genetic architecture for the set of complex psychiatric traits. Generally, the genetic 
architecture of the vast majority of neuropsychiatric disorders is composed by highly polygenic and 
heterogeneous factors including multiple risk alleles, epistatic and epigenetic effects. Risk alleles can 
individually be common or rare, and can include, for example, single nucleotide polymorphisms 
(SNPs) and copy number variants (CNVs, Gelernter 2015). 
Common neuropsychiatric disorders are among the most complex and poorly understood conditions 
affecting the human body. In recent years there have been major research efforts to improve our 
understanding of their complex genetic predisposition. Initial studies included genetic linkage 
studies, candidate gene association studies and targeted sequencing studies, which follow a 
hypothesis-driven approach. Although these “traditional” approaches have identified a few 
susceptibility genes, these studies did not succeed to identify common major susceptibility loci. The 
scenario started to change with the advent of genome-wide association studies (GWASs) which 
allowed a more systematic, hypothesis-free exploration of the genetic basis of neuropsychiatric 
disorders. The hypothesis-free approach of a GWAS offered the opportunity to overcome difficulties 
and obstacles enforced upon the incomplete understanding of the pathophysiology of the disease 
(Kitsios & Zintzaras 2009). 
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1.2 Genetic strategies for the dissection of the genetic architecture of 
neuropsychiatric disorders 
A GWAS is usually designed as a case-control association study, in which allelic variation of SNPs is 
compared between individuals with a particular disease and unaffected individuals. The strategy of 
the GWAS approach is mainly directed on the discovery of common variants conferring 
low/moderate risks following the “common disease/common variant” hypothesis (Reich & Lander 
2001). This hypothesis predicts that the genetic risk for common diseases will often be due to 
disease-predisposing alleles with relatively high frequencies. In the last few years, a huge number of 
GWASs have been performed to dissect the genetic basis of many different complex diseases and 
traits. GWASs investigating the genetic architecture of neuropsychiatric disorders have identified 
many susceptibility variants (Psychiatric GWAS Consortium Bipolar Disorder Working Group 2011; 
Sullivan et al. 2012). The National Human Genome Research Institute (NHGRI) catalog of published 
GWAS hits harbors more than 15,000 SNPs associated with human diseases, of which more than 
2,000 SNPs are associated with neuropsychiatric disorders (Welter et al. 2014). However, the 
identified genetic variants characteristically explain only a modest proportion of the total heritability 
of these traits. This has led to the common question, how the “missing heritability” of complex 
diseases can be explained (Eichler et al. 2010). One plausible explanation is that most of GWASs have 
SNPs with minor allele frequencies of more than 5% implying that many rare variants has not been 
ascertained by current GWASs. According to the alternative “common disease/rare variant” 
hypothesis, complex traits are caused collectively by multiple rare DNA sequence variants, each with 
moderate to high penetrance (Marian 2012). To test this hypothesis, gene sequencing studies have 
been carried out by next-generation sequencing (NGS) methods: either as target candidate gene 
studies and whole exome or genome studies (Bamshad et al. 2011). Although NGS has identified 
many deleterious gene mutations, the current findings do not close the gap of the missing heritability 
(Petronis 2010; Liu & Leal 2012). One problem arises by the difficulty to interpret the biological effect 
of variants identified by GWASs (Westra & Franke 2014). Typically, a candidate region identified by a 
GWAS contains more than one gene and multiple sequence variants form a linkage disequilibrium 
(LD) block (Albert & Kruglyak 2015). Although variants that alter coding sequences are obvious 
candidates, the majority of loci identified in GWASs is found in non-coding regions and probably 
affects regulatory elements (Maurano et al. 2012). It is difficult to unequivocally identify the causal 
variant for each locus by using the traditional fine-mapping methods. Several lines of evidence 
suggest that many sequence variants in non-coding regions influence regulatory processes 
controlling mRNA transcription. 
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1.3 Genome- and epigenome-wide projects 
I presume that the understanding of the molecular mechanisms underlying common diseases will be 
improved by an integrated functional genomics strategy. By 2004, large-scale genome projects 
already indicate that genome sequences alone cannot explain the whole diversity of life, because 
they are very similar within and across species (cf. Ptashne et al. 2010). Instead, epigenetics may 
explain how these similar genetic codes are differentially expressed in different cell-types within 
different environmental conditions and at different times (Ptashne et al. 2010). Epigenetics refers to 
heritable changes in gene expression caused by alterations in DNA methylation and chromatin 
structure (Henikoff & Matzke 1997). Epigenetic factors have been linked to developmental processes 
and play a critical role in normal cellular differentiation during embryogenesis (Li 2002). They have 
been implicated to play an important role in several human diseases, including cancer and 
neuropsychiatric disorders (Dalton et al. 2014). Epigenomics is the science of functional elements 
regulating gene expression in cells. The epigenome consists of the complete collection of epigenetic 
marks, such as DNA methylation, histone modifications and non-coding RNAs that exist in a cell at 
any given point (Romanoski et al. 2015). 
Ongoing projects such as ENCODE (Encyclopedia of DNA Elements), the International Human 
Epigenome Consortium (Bae 2013) and the US National Institutes of Health Epigenomics Roadmap 
are generating cell-specific reference data sets that provide a basis for delineating the complex 
interplay between epigenomic processes and the transcriptome. The ENCODE project aimed to 
catalog the regulatory elements in human cells and to study the epigenomic signatures of cells which 
are grown in culture (ENCODE Project Consortium 2004, 2007, 2012). Additional approaches and 
projects further benefit from the ENCODE project (Civelek & Lusis 2014): Systematic maps of 
transcription factor binding sites and chromatin modifications have been generated as have 
databases and web-tools such as GWAS3D (Li et al. 2013), which help to automate some of the 
processes involved. In addition, the Roadmap Epigenomics Project extends the ENCODE project and 
aims to elucidate how epigenetic processes contribute to human biology and disease (Kundaje et al. 
2015). The researchers have linked epigenomic signatures to the corresponding genetic information, 
producing reference epigenomes for several human tissues and cell-types. The result is a 
comprehensive landscape of epigenomic elements regulating gene expression in the human body 
(Romanoski et al. 2015). Kundaje and co-workers (2015) enable insights into the epigenomic 
landscape, its dynamics across cell-types or tissues and development. Their epigenomic data sets, 
regulatory annotation and integrative analyses have resulted in the most comprehensive map of the 
human epigenomic landscapes so far and cover the largest collection of primary cells and tissues 
(Kundaje et al. 2015). Some of the most widely studied mechanisms of epigenetic regulation include 
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DNA methylation, histone modifications as well as non-coding RNAs. DNA methylation is the most 
stable of all epigenetic modifications and the most studied epigenetic modification to date (Beck & 
Rakyan 2008; Dalton et al. 2014). 
 
1.4 DNA methylation 
DNA methylation is the only epigenetic mark for which a detailed mechanism of mitotic inheritance 
has been described (Bird 2002). The most common form of DNA methylation in vertebrates is 5-
methylcytosine (5mC), which arises by the addition of a methyl group to cytosine nucleotides (C) and 
affects 70 to 80% of CpGs in the human genome (Ehrlich et al. 1982). High levels of 5mC in promoter 
regions that are CpG-rich are strongly associated with transcriptional repression, whereas genomic 
regions that are CpG-poor exhibit a more complex relationship between DNA methylation and 
transcriptional activity (Jones 2012). DNA methylation has become an important tool in the emerging 
systems approach to explore and better understand genome function in health and disease. DNA 
methylation has been extensively studied for its role in several biological processes such as for 
example genomic imprinting (Barlow 2011) and characteristic changes in DNA methylation have been 
reported for cancer (Baylin & Jones 2011; Shames et al. 2013) and several other diseases (Feinberg 
2007). 
Over the past decade, numerous approaches have been evolved for methylation analysis. Recent 
advances in NGS and microarray technology allow mapping of DNA methylation at a high genome-
wide resolution and in a large number of samples (Laird 2010). These new methods create enormous 
opportunities for research of the epigenome (Bock 2012). Key advantages of the NGS technology are 
its comprehensive genomic coverage, high quantitative accuracy and excellent reproducibility (Bock 
2012). But the most widely-used approach for epigenome-wide DNA methylation analysis is the 
Illumina Infinium Human Methylation450 BeadChip microarray (HM450). The HM450 microarray 
offers a powerful tool to assess DNA methylation across the genome. The genomic coverage of the 
Infinium assay is more limited than that of most bisulfite-sequencing based methods, but the 
compatibility with existing genotyping pipelines, the lower per-sample cost compared with whole-
genome bisulfite sequencing and the simpler analysis and interpretation of methylation data makes 
it an attractive approach for large-scale sample collections (Bock 2012; Morris & Beck 2015). 
Verification and validation are usually done using locus-specific DNA methylation assays at a small 
number of CpGs in many samples to reduce the cost of studying large validation cohorts. For this 
purpose the most popular method is pyrosequencing (Tost & Gut 2007; Potapova et al. 2011). 
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1.5 Quantitative trait loci (QTLs) 
In 2001, Jansen and Nap introduced the concept for a strategy, coined ‘genetical genomics’ to 
identify which genes are regulated by genetic variation (Jansen & Nap 2001). By correlating genetic 
variants with intermediate molecular quantitative traits, such as methylation levels or gene 
expression levels, it is possible to identify quantitative trait loci (QTLs). To identify the variants that 
influence DNA methylation or gene expression, two types of data must be collected from each 
individual. First, the genotype data of each individual are required. Second, in each individual the 
DNA methylation is measured using an array platform considering genome-wide patterns or the 
expression of each gene in the genome is measured using either expression microarrays or RNA 
sequencing. The QTLs are then identified by comparing the genotypes with the methylation or 
expression levels using a statistical association test. During that course, individuals are grouped 
according to the allele they carry. A significantly higher methylation or expression level for a gene in 
one group than in the other group suggests that the variant (or another variant in LD) influences the 
methylation or expression of this gene. The test is repeated at every DNA variant in the genome 
which results in a genome scan for methylation quantitative trait loci (meQTLs) or expression 
quantitative trait loci (eQTLs) for this gene (Albert & Kruglyak 2015). 
QTLs can be divided into those that have local effects (cis-QTLs), meaning that the genetic variant is 
located near the genomic probe and those with distant effects (trans-QTLs), meaning that the genetic 
variant is located further away from the genomic probe (e.g. >10 Mbps apart or on a different 
chromosome; Januar et al. 2015). Recent studies have examined the association between genetic 
variants and the quantitative traits in both cis and trans, of which cis-acting QTLs predominate (Gibbs 
et al. 2010; Zhang et al. 2010; Bell et al. 2011; Numata et al. 2012; Westra et al. 2013; Ramasamy et 
al. 2014; Schramm et al. 2014). Distant QTLs have smaller effects sizes and seem also to be more 
tissue-specific than local QTLs which are often conserved among various tissues (Petretto et al. 2006; 
van Nas et al. 2010; Fairfax et al. 2012), which further complicates the detection of those trans-acting 
QTLs. Overall, previous reported studies show that the genetic regulation of gene expression is 
complex and differs widely across cell-types and tissues, especially for genetic variants that are 
disease-associated.  
The choice of tissue type is a major challenge that distinguishes genetic and epigenetic studies. The 
tissue type is largely irrelevant for genetic studies of germline genetic variation in contrast to 
epigenetic studies where often the primary disease- or exposure-relevant target tissue (or cell-type) 
is available on a limited scale, e.g. brain tissue (Mill & Heijmans 2013). So far, several QTL studies 
have investigated human brain tissue in neuropsychiatric disorders (Gibbs et al. 2010; Zhang et al. 
2010; Numata et al. 2012; Gamazon et al. 2013; Kim et al. 2014; Numata et al. 2014; Ramasamy et al. 
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2014; Smith et al. 2014), but all of them performed QTL analyses in postmortem brain tissue. 
Postmortem studies of brain tissue have several limitations: postmortem brain tissue samples have 
restrictions with respect to mRNA conservation (Bray et al. 2003; Webster et al. 2009) and methods 
of tissue preservation alter the quality of biomolecules obtained (Januar et al. 2015). A delay of the 
autopsy of postmortem brain tissue alters DNA methylation profiles from baseline (Miller-Delaney et 
al. 2015). Additionally, postmortem studies of brain tissue are critical for understanding the disease 
aetiology (Januar et al. 2015). On the one hand these aspects indicate the need for fresh frozen 
human brain tissue obtained from living patients. On the other hand it is necessary to explore the 
extent to which easily accessible cells obtained from tissues such as whole blood can be used to 
address questions about epigenomic variation in inaccessible tissues such as the brain. 
Known and unknown confounders can contribute significantly to the dataset variance in quantitative 
epigenomic high throughput analyses, so the integration of major confounding factors are required 
to perform a successful analysis of QTL data (Januar et al. 2015). Potential confounders include age, 
gender and ethnic diversity. Further, medical histories of participants, such as antiepileptic 
treatments, antipsychotic or antidepressant medications are useful and necessary. Studies that use 
postmortem brain tissue also have to consider confounders such as antemortem history, medication 
use and cause of death or postmortem delay. Another important issue when performing QTL studies 
is cellular heterogeneity. To overcome this issue, methods of adjusting for DNA methylation 
variability associated with cell composition differences have been developed for brain as well as for 
blood cells and can be incorporated in statistical models for adjustment (Houseman et al. 2012; 
Guintivano et al. 2013; Jaffe & Irizarry 2014). Cellular heterogeneity provides an important issue but 
only a few current studies start to consider this confounding factor. 
1.5.1 Methylation quantitative trait loci (meQTLs) 
The association between genetic variants and the disorder could be mediated via its ability to 
influence DNA methylation (meQTLs). Because sequence variation can directly influence DNA 
methylation in cis (Schalkwyk et al. 2010) and evidence already provides an enrichment of meQTLs at 
loci for several disorders identified by GWAS (Numata et al. 2012; Gamazon et al. 2013; Smith et al. 
2014), it is likely that interpretation of genetic data can be largely improved by integrating allele-
specific epigenetic information into the analyses (Meaburn et al. 2010). 
Early meQTL studies focused on methylation data from relatively few CpGs showing a strong bias 
towards promoter regions. The comprehensive array platform considering genome-wide patterns 
enable recent studies to cover much more meQTLs. The present study uses the popular platform of 
the HM450 array that is the best known platform capable of high-throughput work. However, 
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technical artifacts need to be taken into account, especially where Infinium probes overlap with 
positions of known DNA variants (Barrow & Byun 2014). When using microarray platforms and 
studying meQTLs regarding SNPs whose genotype correlates with DNA methylation, potential SNP 
artifacts represent a substantial challenge (Barrow & Byun 2014). Removing of all SNP-associated 
probes from the analysis process would not be appropriate as 56% of the probes on the Infinium 
array contain SNPs. Definite factors such as the distance of an SNP within the probe and the minor 
allele frequency within the ethnicity of the study population should be considered. It is important to 
give careful consideration to what parameters should be set and potential confounding factors 
should be subsequently excluded without minimizing the HM450 probe set excessively. Up to date 
only few meQTLs have been reported to change gene expression (Gibbs et al. 2010; Gamazon et al. 
2013; Gutierrez-Arcelus et al. 2013). The present study addresses this promising issue. 
1.5.2 Expression quantitative trait loci (eQTLs) 
Expression quantitative trait loci (eQTLs) are regions of the genome which contain DNA sequence 
variants that influence the expression level of one or more genes (Albert & Kruglyak 2015). The 
genetics of expression variation of single genes has been studied for a long time, at least since 1962 
(Schwartz 1962). Maps of eQTLs are being built in large-scale studies in humans for different cell-
types or tissues, such as blood cells and brain tissue (Gibbs et al. 2010; Westra et al. 2013; Kim et al. 
2014; Ramasamy et al. 2014; Schramm et al. 2014). 
Beyond the hitherto description of large eQTL catalogs, the understanding of the role of regulator 
variation is currently being expanded in two directions. Typically, eQTLs were identified as ‘loci’, 
statistical associations between regions of the genome and the expression of genes. Recently, eQTLs 
are being used to identify the causal variants and their molecular mechanism of action. One 
immediate application of eQTLs lies in the interpretation of GWAS risk loci. Large eQTL studies can 
help to prioritize potential causal variants among multiple polymorphisms within the GWAS 
candidate regions (Albert & Kruglyak 2015). 
1.5.3 Imprinted methylation quantitative trait loci (imeQTLs) 
Imprinting meQTL (imeQTL) analyses imply the association of SNP genotypes of defined parental 
origin with methylation levels. Genes that show a parental bias in methylation will undergo 
differential regulatory effects from the paternal and maternal alleles. As standard association studies 
treat both alleles equally, they are unable to detect effects such as imprinting in which the two 
alleles are differentially regulated. 
Genomic imprinting is a form of epigenetic variation whereby Parent-of-Origin (PofO) specific 
epigenetic modifications are inherited by offspring, resulting in mono-allelic gene expression. 
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Aberrations in normal imprinting patterns have been linked to congenital disorders such as Prader-
Willi / Angelman syndromes (Nicholls et al. 1989; Clayton‐Smith 1993), and Beckwith-Wiedemann 
syndrome (Reik et al. 1995). This finding is consistent with the fact that many imprinted genes have 
prominent roles in growth and development (Georgiades et al. 2001; Lambertini et al. 2012). Recent 
GWASs have taken into account potential PofO effects and have uncovered important contributions 
of imprinting to common complex diseases (Kong et al. 2009). In addition to genetic studies, 
epidemiological data in many common diseases, including multiple sclerosis (Chao et al. 2010), 
asthma (Carroll et al. 2005), and bipolar disorder (McMahon et al. 1995; Kornberg et al. 2000) further 
imply that PofO and imprinting-mediated effects on disease may be pervasive. But despite evidence 
for the significant impact of imprinting in genome function and disease, catalogs of imprinted genes 
in the human genome are almost certainly incomplete. At present, there are >120 known imprinted 
genes in mice; yet in humans, only approximately 85 have been confirmed (www.geneimprint.com; 
Wei et al. 2014), 10% of which have been identified since 2012 (Barbaux et al. 2012). The imprinting 
meQTLs of the present study may help to identify additional imprinted genes which display both 
allele specific CpG methylation and genomic imprinting. The imeQTL study of this work will help to 
identify PofO dependent susceptibility effects that may improve the analytical power of GWASs to 
dissect the complex genetic architecture of common brain disorders and may explain a substantial 
fraction of the missing genetic heritability. 
 
1.6 Perspectives 
The field of epigenetics is expanding at an exponential rate and projects like the Roadmap 
Epigenomics Consortium (Romanoski et al. 2015) makes huge efforts to fill the gap of epigenomic 
studies and its association with human disease. Systems genetics studies are aiming to identify the 
role of regulatory variation in complex traits by integrating intermediate phenotypes, such as CpG 
methylation, transcript, protein or metabolite levels (Civelek & Lusis 2014; Albert & Kruglyak 2015). 
Recent reviews present a survey about the current knowledge of the molecular architecture of 
complex traits and are useful for the identification of genes and pathways that underlie common 
human diseases. However, our understanding of the exact mechanisms by which epigenetic changes 
modify a phenotype, particularly in association with common neuropsychiatric disorders in humans, 
is still limited. Current research in this area is limited by a number of factors including difficulties in 
establishing functional causality, tissue heterogeneity and other confounding factors such as spatial 
and temporal effects (Januar et al. 2015). The understanding of the role of the methylome in 
regulating human health and disease is yet at the beginning. This is particularly true in the field of 
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neuropsychiatric disorders for which access to pathogenic brain tissue is usually not available in living 
patients. 
1.7 Objectives 
The present study aims to get a deeper insight into the role of regulatory variation in complex traits, 
especially in neuropsychiatric disorders, with a particular interest in mapping the effects of common 
genetic variants on gene expression and DNA methylation. An integrative functional model of 
genomics and epigenomics will be optimal for understanding the etiological pathways to common 
disorders with complex genetic predisposition, such as neuropsychiatric disorders. An integrative 
functional approach will further help to trace molecular changes through layers of biological 
information to the disease outcome. 
Functional genomics studies of common brain disorders are difficult because human brain tissue is 
usually not available. Temporal lobe epilepsy (TLE) offers a unique opportunity to obtain bioptic brain 
specimens when epilepsy surgery is necessary to control pharmacoresistant seizures (Grote et al. 
2015). I used this intriguing resource to perform the first meQTL and eQTL study of bioptic human 
brain tissues of pharmacoresistant mesial TLE (mTLE) patients. Additionally, the approach of the 
present study allows a systematically examination of the influence of cis-meQTLs on gene expression 
to delineate methylation-driven genes in fresh frozen brain tissue. 
Currently, there are no QTL studies, which consider cellular heterogeneity among different brain 
regions and focus on neuropsychiatric disorders. Thus, the present study considers two major 
aspects of epigenetic studies including tissue relevance, as I can use tissue in which the given disease 
emerges, and cellular heterogeneity. 
An intra-individual cross-tissue study concluded that between-tissue variation in DNA methylation 
greatly exceeds inter-individual differences for any one tissue but suggested that some inter-
individual variation in DNA methylation may be correlated between brain regions and blood (Davies 
et al. 2012). To explore tissue-specifity of the cis-meQTLs detected in hippocampal brain tissue, 
meQTL analyses in whole blood cells of 496 German population controls without neuropsychiatric 
disorders were performed, using the same array platform and analytical procedures. This may offer 
the opportunity to dissect accessible biomarkers in blood DNA sources for common brain disorders. 
One major achievement of this study will be a public release (publication in preparation) of a 
database reporting the complete meQTL and eQTL findings of this thesis. These genome-wide maps 
of meQTLs and eQTLs will improve the prospects to elucidate the genetic mechanisms determining 
DNA methylation and gene expression in common brain disorders. 
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2. MATERIALS AND METHODS 
Genome-wide methylation quantitative trait loci (meQTL) and expression quantitative trait loci 
(eQTL) analyses were performed in fresh frozen hippocampal brain tissue of European patients with 
pharmacoresistant mesial temporal lobe epilepsy (mTLE). Individual high-density SNP genotypes 
were correlated with individual quantitative methylation states and individual expression levels. To 
delineate accessible epigenetic biomarkers, genome-wide maps of meQTLs were also generated in 
whole blood cells from German population controls using the same methylation microarray. In 
addition, blood cell DNA samples of parent-offspring trios with Genetic Generalized Epilepsy (GGE) 
were investigated to screen for differentially methylated parental genomic regions (imprinting 
meQTLs, imeQTLs). 
 
2.1. Study participants and surgical specimens 
2.1.1 Fresh frozen hippocampal brain tissue 
The present study included 117 pharmacoresistant mTLE patients of European descent who 
underwent surgical treatment in the Epilepsy Surgery Program at the University of Bonn Medical 
Center (Wiebe et al. 2001). In all patients, presurgical evaluation using a combination of noninvasive 
and invasive procedures revealed that seizures originated in the mesial temporal lobe (Kral et al. 
2002). Surgical resection of the hippocampus was clinically indicated in every case (Pernhorst et al. 
2011). Informed written approval was obtained from all patients and procedures were in accordance 
with the Declaration of Helsinki and approved by the local ethics committee. 
All fresh frozen hippocampus tissue samples were from identical regions of the hippocampus. Fresh 
frozen sections were analyzed according to international standards and the diagnostic classification 
was established by an experienced neuropathologist according to international criteria (Becker et al. 
2003; Blumcke et al. 2007). The majority (> 60%) of the hippocampi specimens displayed Ammon’s 
horn sclerosis (AHS; segmental neuronal cell loss and concomitant astrogliosis and microglia 
activation). A smaller proportion of the specimens showed predominantly lesional alterations such as 
cortical dysplasia or tumors. Up to five 20 µm thick tissue sections were used for the preparation of 
genomic DNA and mRNA. DNA was isolated from tissue specimens using the DNeasy Blood and 
Tissue Kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol (Schonberger et al. 
2009). mRNA was isolated from tissue specimens using the Dynabeads mRNA Direct Micro Kit (Dynal, 
Oslo, Norway) following the manufacturer’s protocol (Fassunke et al. 2008). Complementary DNA 
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(cDNA) was synthesized by reverse transcription of total mRNA using the RevertAid First-Strand cDNA 
Synthase Kit (Fermentas, St. Leon-Rot, Germany) according to the manufacturer’s protocol. 
All 117 mTLE patients fulfilled the inclusion criteria by having mRNA-expression data, DNA 
methylation data and genotypes in sufficient quality. Two patients were excluded because of their 
outstanding disease type (Rasmussen's encephalitis). Conclusively, analyses have been performed on 
115 hippocampal brain tissue samples (60 males, 55 females; range of age of seizure onset: 
1-47 years, average age: 11.1). The mTLE patient group was clinically characterized with respect to 
seizure manifestation. The clinical parameters of the mTLE patients are summarized in Appendix, 
Table 6-1. 
2.1.2 Whole blood cells from German population controls 
A population-based cohort of 498 unrelated German population controls without neuropsychiatric 
disorder (273 males, 225 females; age range: 54 – 74 years, average age: 57.4) was collected from 
the Western regions of Germany (Ruhr area) within the framework of the cardiovascular longitudinal 
Heinz Nixdorf RECALL study (HNR; Schmermund et al. 2002). Of the 498 population controls two 
individuals did not fulfill the inclusion criteria having DNA methylation data and genotypes in 
sufficient quality. Hence, analyses have been performed on 496 population controls.  
2.1.3 Whole blood cells from parent-offspring trios with GGE 
Epilepsy patients of European ancestry with common GGE syndromes, including genetic absence 
epilepsies (GAE), juvenile myoclonic epilepsy (JME) and epilepsies with generalized tonic clonic 
seizures alone (EGTCS) exhibiting generalized spike and wave discharges in their resting 
electroencephalogram (gsw-EEG), were recruited in a multi-center effort from the European EPICURE 
Project (http://www.epicureproject.eu). The diagnostic classification of GGE syndromes were 
prepared according to EPICURE guidelines and standardized phenotyping protocols 
(http://portal.ccg.uni-koeln.de/ccg/research/epilepsy-genetics/sampling-procedure/; ILAE 1989; 
Nordli 2005; Berg et al. 2010). Individuals with a history of major psychiatric disorders (autism 
spectrum disorder, schizophrenia or affective disorder) or severe intellectual disabilities were 
excluded (Trucks 2013). In total, 269 parent-offspring trios of European origin with offspring affected 
by GGE were available for imeQTL analysis (103 male trio children, 166 females; range of age of 
seizure onset: 2 – 21 years, average age: 9.8). Trios were recruited from different European countries 
or countries with European ancestry, including Australia (N = 69), Bulgaria (N=2), Denmark (N = 20), 
Germany (N = 14), Italy (N = 138), and Turkey (N = 26). The offspring trios were affected by the 
following GGE syndromes: 175 GAE, 92 JME, and 2 EGTCS alone. All study participants gave informed 
consent according to the regulations at their local institutional review boards. 
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2.2 Genome-wide high-density SNP genotyping 
Genome-wide high-density SNP genotyping was carried out by using different SNP genotyping arrays 
for the different study cohorts. For the mTLE patients SNP genotyping was performed using the 
Illumina HumanHap550 SNP array (550k SNPs; Illumina, San Diego, CA, USA). For the HNR controls 
two genotyping arrays, Illumina HumanOmniExpress 12 v1.1 and Illumina HumanOmni1 Quad v1.0 
(overlap of 539k SNPs; Illumina, San Diego, CA, USA) were combined. For the GGE offspring trios the 
Affymetrix Axiom Genome Wide Human genotyping array (567k SNPs; Affymetrix, Santa Clara, CA, 
USA) was used. To ensure a high accuracy of the SNP genotype calls, several quality filters were 
applied for the individual array and the single SNP. Exclusion criteria for SNP arrays were: call rate 
per array < 97%, and autosomal heterozygosity rate > 29%. Exclusion criteria for SNPs were: i) non-
autosomal position, ii) missing hg19 annotation, iii) call rate per SNP < 97%, and iv) European minor 
allele frequency (MAF) < 5% from the 1000 Genomes Project. In addition, the trio pedigree structure 
and the relationship of all trio members was checked with the PedigreeExplorer 
(http://pedigreeexplorer.meb.uni-bonn.de/) and by IBD-estimation and was further visualized with 
GRR (graphical representation of relationship errors; Abecasis et al. 2001). All quality control (QC) 
procedures were carried out using Plink, version 1.9 (http://pngu.mgh.harvard.edu/purcell/plink/, 
Purcell et al. 2007). 
2.2.1 SNP imputing 
SNP imputing is a useful method that can detect causal variants that use the linkage disequilibrium 
(LD) structure in a genomic segment to infer the alleles of SNPs which are not directly genotyped 
(Marchini et al. 2007). The pre-phasing based imputation was carried out using a combination of the 
programs SHAPEIT2 and IMPUTE2 (Howie et al. 2012). Imputation with IMPUTE2 was based on the 
reference panel: 1000 Genomes Phase I release of NCBI build 37 (hg19). The imputed SNP genotypes 
were additionally quality filtered using SNPTESTv2 (Marchini et al. 2007). Imputed SNPs were 
excluded from further analyses according the following criteria: i) SNPtest info quality value < 0.9, ii) 
MAF < 5%, iii) missing data proportion > 3% using Plink 1.9. Furthermore, a LD-based SNP pruning 
was performed, considering a window of 50 SNPs, followed by a LD calculation between each pair of 
SNPs in the window and removal of one SNP of SNP pairs with a LD r2 > 0.8. 
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2.3 DNA methylation analysis 
2.3.1 Bisulfite treatment of genomic DNA  
All methylation profiling technologies of Illumina are based on genotyping bisulfite-converted DNA. 
The EZ DNA Methylation Kit from Zymo Research (Zymo Research, Irvine, CA, USA) was used for 
bisulfite treatment of genomic DNA samples. The kit is based on the divergent reaction of 
unmethylated vs. methylated cytosine and sodium bisulfite: unmethylated cytosine is converted into 
uracil while methylated cytosine is protected and remains cytosine (Zilberman & Henikoff 2007). 
Following PCR, the converted uracil nucleotides will be detected as thymine.  
A standardized bisulfite conversion protocol was used. Genomic DNA was applied according to the 
manufacturer’s protocol of the Zymo EZ DNA Methylation kit (#D5001). Alternative incubation 
conditions are recommended, which differ from the normal manufacturer’s protocol, when the 
Illumina Infinium methylation assay is used. This step based upon Illumina’s feedback to Zymo 
Research that bisulfite conversion efficiency can be improved by incorporating a cyclic denaturation 
protocol during the process of conversion. 
2.3.2 Array-based genome-wide assessment of CpG methylation 
For mapping CpG methylation level of genomic bisulfite-converted DNA the Infinium Human 
Methylation450k BeadChip array (HM450; Illumina, San Diego, CA, USA) was used. The HM450 array 
assesses the methylation levels of 485,577 CpG sites (482,421 CpG sites, 3,091 non-CpG sites and 65 
random SNPs) and uses the Infinium methylation assay. 
The CpG probes of the HM450 BeadChip are located in 21,231 RefSeq genes and 26,658 UCSC 
annotated CpG islands (CGI), as well as in genomic regions such as 5’ and 3’ UTRs, gene body and 
promoter. The 5´-regulatory gene region was divided into two blocks of 200 bps (TSS200) and 1,500 
bps (TSS201-TSS1500) upstream of the transcription start site (TSS). The CGI region was further 
extended by including the 2 kb regions flanking CpG island shores (N = 26,249) as well as the CpG 
island shelves (2 kb regions upstream and downstream of the CpG island shores; N = 24,018; Bibikova 
et al. 2011).  
The Human Methylation450 BeadChip applies both Infinium I and II assay chemistry technologies to 
quantitatively assess the methylation state of bisulfite-treated CpG sites. Both Infinium probes are 50 
bases long, but detection of the methylation levels occur by different mechanisms. One bead type of 
the Infinium I assay corresponds to methylated (C), another bead type to unmethylated (T) state of 
the CpG site. Both bead types for the same CpG locus incorporate the same type of labeled 
nucleotide, determined by the base preceding the interrogated “C” in the CpG locus, and will be 
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detected in the same color channel. For the Infinium II assay only one bead type corresponds to each 
CpG locus. Each locus will be detected in two colors (red and green fluorescence signals) by single-
base extension (SBE) which reflects the methylation state (Bibikova et al. 2011). The Infinium 
methylation assay was performed following the standard Infinium protocol. 
2.3.3 Assessment of signal intensities 
Infinium methylation data was processed with the Methylation Module of the GenomeStudio 
software (v2011.1) using HumanMethylation450 manifest v1.1. The GenomeStudio Methylation 
Module calculates methylation level of each CpG locus as methylation beta-value (β-value, see 
below) using the ratio of intensities between methylated and unmethylated alleles (Bibikova et al. 
2011). These β-values were exported and used for further analyses. In addition, the GenomeStudio 
Methylation Module has an Infinium Methylation Controls Dashboard which provides a couple of 
quality parameter like staining, hybridization, extension, bisulfite conversion and specificity. This 
Control Dashboard gives an overview of the technical quality of the array and the array run. 
2.3.4 Normalization of signal intensities 
The brain and blood methylation arrays were SWAN (subset-quantile within array normalization; 
Maksimovic et al. 2012) corrected and quantile normalized using the Bioconductor R-packages 
preprocessCore and minfi. The SWAN performs an independent normalization of six probe categories. 
The categories are defined by the differentiation of type I and II Infinium probes and in combination 
with the CpG number in the probe-body (one to three). Using the SWAN method technical variability 
within and between arrays could be reduced. To increase the performance in terms of detection and 
true positive rate of highly methylated and unmethylated CpG sites (Du et al. 2010) ß-values where 
transformed to M-values (see below) and subsequently quantile normalized between the arrays 
(Figure 2-1). The resulting M-values where further checked for general signal deviances in a principle 
component analysis (PCA). PCA was performed using a correlation dispersion matrix and normalized 
Eigenvector scaling (prcomb, stats R-package). 
MATERIALS AND METHODS 
15 
 
 
Figure 2-1: Normalization and transformation effects. 
The distribution of signal values without normalization (A, B), using within array SWAN normalization (C), using within array 
SWAN normalization and between arrays quantile normalization (D) and using M-value transformation (B - D) is plotted. 
 
The β-value is defined as the ratio of the methylated probe intensity and the overall intensity (sum of 
methylated and unmethylated probe intensities), ranging from 0 to 1. For an ith interrogated CpG site 
ß-value is defined as: 
𝛽𝑖 =  
max (𝑦𝑖,𝑚𝑒𝑡ℎ𝑦 , 0)
max(𝑦𝑖,𝑢𝑛𝑚𝑒𝑡ℎ𝑦 , 0) + max(𝑦𝑖,𝑚𝑒𝑡ℎ𝑦 , 0) +  𝛼
 
yi,methy and yi,unmethy are the intensities measured by the i
th methylated and unmethylated probes, 
respectively. Ideally, a value of zero indicates that all copies of a CpG site are completely 
unmethylated (no methylated molecules are measured) and a value of one indicates that every copy 
of the site is methylated. In contrast, the M-value is calculated as the log2 ratio of the intensities of 
methylated probe versus unmethylated probe as shown in the following equation: 
𝑀𝑖 = log 2 (
max(𝑦𝑖,𝑚𝑒𝑡ℎ𝑦 , 0) +  𝛼
max(𝑦𝑖,𝑢𝑛𝑚𝑡ℎ𝑒𝑦 , 0) +  𝛼
) 
It has a range from positive to negative values. An M-value close to 0 indicates a similar intensity 
between the methylated and unmethylated probes, which means that the CpG site is about half-
methylated. The meaning of positive M-values is that more molecules are methylated than 
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unmethylated, while negative M-values mean the opposite. M-values have been widely used in 
expression microarray analysis, especially two-color microarray analysis and are more statistically 
valid for differential methylation analysis of methylation levels of CpG loci. In the present work M-
values are particularly used for demonstrating methylation levels. 
2.3.5 Quality control filters of CpG methylation profiles 
To ensure a high accuracy of the CpG methylation profiles several quality control filters were applied 
– mainly based on the previous work of Chen and colleagues (2013): i) CpG probe sets were filtered 
according to hg19 autosomal representation, ii) CpG detection signal had to be sufficient (P-value > 
0.01 in > 5% of the samples), and iii) SNPs in the cg 50mer probe with MAF > 1% using the 1000 
Genomes Project (release 20110521) were excluded. Additionally, CpGs that overlap known SNPs, so 
called polymorphic CpGs, were excluded. A CpG site was defined to be polymorphic if a SNP resided 
at the position of the cytosine or guanine on either strand, and for Infinium I assays, if a SNP resided 
at the position where SBE occurs (base before C). Furthermore, nonspecific probes (aka as cross-
reactive probes, Chen et al. 2013) on the Illumina 450K array, i.e. probes which co-hybridize to 
alternate sequences which are highly homologous to the intended targets (ca. 6%) were excluded. In 
total, a set of QC-filtered 362,722 CpG probes remained of the original 485,577 CpG probe set for the 
regression statistics (see below 2.5). 
 
2.4 mRNA expression analysis 
For mapping mRNA expression of the 115 mTLE patients the Illumina HumanHT-12 v3 Expression 
BeadChip (Illumina, San Diego, CA, USA) was used. Each array on the HumanHT-12 v3 Expression 
BeadChip targets more than 48,000 probes which were derived from the National Center for 
Biotechnology Information Reference Sequence (NCBI, RefSeq) (Build 36.2, Release 22) and the 
UniGene (Build 199). 
Raw intensity values for each mRNA expression probe were generated in the Department of 
Genomics, Research Center Life & Brain at Bonn University, Germany, using the HumanHT-12 v3 
BeadChips. Subsequently, mRNA expression data were quantile normalized on probe level and 
without background correction using Illumina GenomeStudio. The resulting signals were log2 
transformations after offset addition (+16). Exclusion criteria for Illumina HT12 probes included: i) 
probes which were only marginal or not expressed (minimum Illumina detection P-value > 0.05), and 
ii) probes without autosomal (hg19) positioning. Additionally, ambiguous and SNP-containing probes 
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(MAF > 1% in dbSNP 137, 1000 Genomes release 20110521) were excluded for further investigations. 
A set of QC-filtered 31,146 mRNA expression probes was used for regression statistics. 
 
2.5 Statistical quantitative trait loci (QTL) analyses 
QTL analyses investigate the influence of genetic variation (SNPs) and a quantitative trait (CpG 
methylation or mRNA expression). A survey of the integrated data sets for QTL analyses are listed in 
Table 2-1. 
The meQTL and eQTL analyses were performed using the linear regression model of the R-package 
MatrixEQTL (Shabalin 2012). MatrixEQTL is designed for fast and memory efficient QTL analyses on 
large data sets and provides the opportunity of covariate integration without loss of speed. Multiple 
testing corrections were performed in cis and in trans using the false discovery rate (FDR) step up 
procedure of MatrixEQTL (Benjamini & Hochberg 1995). A ± 1 Mbps cis window and a standard 5% 
FDR threshold were used throughout this study. A cis-meQTL or cis-eQTL refer to the most associated 
SNP/CpG or SNP/mRNA pair within the 1 Mbps windows flanking the target CpG or target mRNA 
probe, respectively. Trans-meQTLs or trans-eQTLs will refer to all SNP/CpG or SNP/mRNA pairs 
outside the 1 Mbps windows flanking the target CpG or target mRNA probe respectively. 
Nevertheless, FDR-correction was done over the complete cis or trans data matrix respectively. 
Table 2-1: Survey of the data sets integrated for QTL analyses. 
The available sample cohorts with the number of filtered individuals, CpG sites, mRNA probes and SNPs are listed. 
Condition Count 
Fresh frozen hippocampal brain tissue of mTLE patients:  
meQTL and eQTL analyses with samples having  
- genotype data: HumanHap550, autosomal QC-filtered SNPs (imputed & LD-pruned) 
- methylation data: HM450, autosomal QC-filtered CpG sites 
- expression data: HumanHT12, autosomal QC-filtered mRNA probes 
115 
 
643,195 
362,722 
31,146 
Blood cells of HNR controls: 
meQTL analysis with samples having  
- genotype data: OmniExpress-12 & Omni1-Quad, autosomal QC-filtered SNPs 
- methylation data: HM450, autosomal QC-filtered CpG sites 
496 
 
539,936 
362,722 
Blood cells of GGE parent-offspring-trios:  
imeQTL analysis with samples having  
- genotype data: Axiom, autosomal QC-filtered SNPs (imputed & LD-pruned) 
- methylation data: HM450, autosomal QC-filtered CpG sites 
269 
 
886,110 
362,722 
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2.5.1 meQTL and eQTL analyses in hippocampal brain tissue 
meQTL and eQTL analyses in 115 fresh frozen hippocampal brain tissue were performed using 
gender, age at epilepsy surgery and neuronal proportion as cofactors. Gender (Zhang et al. 2010), 
age at epilepsy surgery (Martino et al. 2013) and neuronal proportion (Guintivano et al. 2013) are 
known confounders with impact on the general CpG methylome. Existence of additional unknown 
confounders with general impact on DNA methylation or RNA expression was investigated by PCA on 
linear regression gender/age/neuronal-proportion residuals. Component loading of the first or first 
and second principal component (PC) were used as additional cofactors in meQTL and eQTL analyses, 
respectively. 
2.5.1.1 Quantification of cell-type heterogeneity 
To quantify neuronal proportions and to generate in silico neuronal profiles following removal of cell-
type heterogeneity bias from DNA methylation profiles (Guintivano et al. 2013) the CETS package in R 
was used. 
The resulting measures were matched with the pathological diagnosis of the proportion of neuronal 
cells in the hippocampal brain tissue. A Spearman rank correlation rho of the clinical parameters 
"nerve cell loss" and "pathology" and the CETS prediction of neuronal cells was calculated. The nerve 
cell loss parameters are positive correlated to each other. The status of lesional mTLE was found to 
be positively correlated to the neuronal cell proportion calculated by the R-package CETS. From a 
clinical point of view, the observed decrease of the neuronal proportion in AHS is plausible and in 
concordance to the pathophysiological observed nerve cell loss in AHS. The CETS proportion of 
neurons is negatively correlated to the nerve cell loss parameters but only significant in CA1 and CA3 
(Table 2-2 & 2-3). 
Table 2-2: Parameters and counts of clinical parameters for hippocampal brain tissue. 
Parameter Total count Feature count 
Pathology N = 115 AHS: N = 79; lesional mTLE: N = 36 
Nerve cell loss CA1 N = 73 AHS: N = 65; lesional mTLE: N = 8 
Nerve cell loss CA2 N = 68 AHS: N = 59; lesional mTLE: N = 9 
Nerve cell loss CA3 N = 67 AHS: N = 58; lesional mTLE: N = 7 
Nerve cell loss CA4 N = 74 AHS: N = 65; lesional mTLE: N = 9 
Abbreviations: AHS, Ammon’s Horn sclerosis; mTLE, mesial temporal lobe epilepsy; CA1 – CA4, hippocampal regions of the 
cornu Ammonis (Ammon’s horn; Blumcke et al. 2007). 
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Table 2-3: Spearman rank correlation rhos and nominal P-values of pairs of parameters. 
 Lesional 
mTLE 
CETS neurons 
(proportion of 
neurons) 
Nerve cell 
loss CA1 
Nerve cell 
loss CA2 
Nerve cell 
loss CA3 
Nerve 
cell loss 
CA4 
Lesional mTLE  0.53 -0.76  -0.40  -0.42  -0.37  
CETS neurons 1.44E-09**  -0.28  -0.02  -0.23  -0.18  
Nerve cell loss CA1 3.12E-23** 2.44E-03*  0.35 0.31 0.23 
Nerve cell loss CA2 1.13E-05** 8.28E-01   1.48E-04**  0.37 0.36 
Nerve cell loss CA3 2.85E-06** 1.53E-02* 8.16E-04** 3.65E-05**  0.85 
Nerve cell loss CA4 3.93E-05** 5.64E-02   1.32E-02*   8.99E-05** 2.01E-33**  
** P < 0.001; * P < 0.05; blue, Spearman rank correlations and red, nominal P-values of pairs of parameters. 
 
2.5.1.2 Principal component analysis (PCA) 
PCAs were calculated using prcomb (stats R-package) on residuals of known confounders (gender, 
age and neuronal proportion) generated by lm (stats R-package). Selection of relevant PC was done 
by scree plots. The scree plots show the proportion of variance accounted for each individual PC. 
Based on the scree plots PC1 was chosen as additional cofactor in meQTL analysis as the amount of 
explained variation dropped after the first component and PC2 as additional cofactor in eQTL analysis 
as the amount of explained variation dropped after the second component (Figure 2-2). These PCs 
have general impact on DNA methylation and mRNA expression, respectively; model for meQTL 
analysis signal ~ gender + age at epilepsy surgery + neuronal proportion + PC1, model for eQTL 
analysis signal ~ gender + age at epilepsy surgery + neuronal proportion + PC1 + PC2. 
            
Figure 2-2: Scree plots. 
On the left side: PCA variance proportion of CpG methylation; on the right side: PCA variance proportion of mRNA 
expression. 
 
A successive addition of the PCs one to 10 to the model followed by additional cis-meQTL and cis-
eQTL calculations respectively was used to estimate the influence of the first ten PCs to P-value 
inflation. The successive addition of PCs led to a very moderate increase of λ only. The lambda 
median for meQTL analysis (CpG) varied from 1.031 to 1.035 and the lambda median for eQTL 
analysis (mRNA) varied from 1.016 to 1.020. In conclusion, I can state that the first ten PCs do not 
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include potential hidden factors which led to a substantial decrease of inflation in cis and can be 
considered robust. 
2.5.2 Methylation-driven gene expression in hippocampal brain tissue 
DNA methylation and gene expression patterns of 115 fresh frozen hippocampal brain tissue samples 
were combined by performing CpG methylation to mRNA gene expression correlation analyses. For 
correlation analyses of meQTL and eQTL of hippocampal brain tissue, the same models as before 
were used (model for CpG methylation to gene expression signal ~ gender + age at epilepsy surgery + 
neuronal proportion + PC1; model for gene expression to CpG methylation signal ~ gender + age at 
epilepsy surgery + neuronal proportion + PC 1 + PC2). Pearson correlation analyses were calculated 
on residuals of the confounders generated by the MatrixEQTL R-package. Multiple testing corrections 
were performed in cis (± 1Mbps) using FDR step up procedure of MatrixEQTL (Benjamini & Hochberg 
1995). For the most associated CpG/mRNA pairs within the 1 Mbps windows flanking the target CpG 
or target mRNA probe, respectively, Pearson correlation coefficients (r-values) were calculated using 
cor (stats R-package). 
Significant CpG/mRNA probe pairs were selected and these pairs were expanded into triplets of SNP 
and CpG/mRNA pairs. The SNPs were significantly correlated in cis with the CpG methylation site (cis-
meQTL finding) and the mRNA transcript probe (cis-eQTL finding) of the respective CpG/mRNA pair. 
The meQTL-SNPs and eQTL-SNPs had to be in LD (r2 ≥ 0.2). 
2.5.3 meQTL analysis in blood cells 
meQTL analysis in 496 HNR blood cells was performed using gender, age of blood withdrawal, cell-
type composition (6 levels), and month of methylotyping (3 of 4 levels) as cofactors. Gender and age 
of blood withdrawal, as well as cell-type composition (Houseman et al. 2012; Jaffe & Irizarry 2014) 
and month of methylotyping (as batch effect; Harper et al. 2013) are known confounders with impact 
on the general CpG methylome. Existence of additional unknown confounders with general impact 
on DNA methylation was investigated by PCA on linear regression gender/age/ cell-type 
composition/ month of methylotyping residuals. 
2.5.3.1 Determination of cell-type composition 
Cell-type composition was performed according to Jaffe and Irizarry (2014) and Houseman et al. 
(2012) which estimate relative proportions of cell-type components in whole blood. Six cell-types 
including CD4+ effector T-cells (CD4T), B-cells (Bcell), Cytotoxic T-cell (CD8T), Natural killer cells (NK), 
Mononuclear white blood cells (Mono) and Granulocytes (Gran) were used. The statistical method by 
Houseman et al. (2012) is virtually the same statistical approach described in Guintivano et al. (2013) 
for estimating neuron and non-neuron components in brain samples. 
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2.5.3.2 Determination of month of methylotyping 
PCA considering four levels of month of methylotyping revealed a strong agglomeration of the factor, 
mainly in the third and fourth PC. The third and forth PC reflect 2.36% and 2.24% of data set 
variance, respectively (Figure 2-3). Therefore, month of methylotyping was added as cofactor. 
 
Figure 2-3: PC variance for four levels of month of methylotyping. 
On the left side: variance of PC 1 & of PC 2; on the right side: variance of PC 3 & of PC 4. The four colors indicate the four 
different months of methylotyping. 
 
2.5.3.3 Principal component analysis (PCA) 
PCAs were calculated using prcomb (stats R-package) on residuals of known confounders (gender, 
age of blood withdrawal, cell-type composition, and month of methylotyping) generated by lm (stats 
R-package). No PC was added as additional cofactor in meQTL analysis of the blood cells as the 
proportion of variance remained steady for all PCs. The PCs have no general impact on DNA 
methylation; model for meQTL analysis signal ~ gender + age of blood withdrawal + cell-type 
composition + month of methylotyping. A successive addition of the PCs one to 10 to the model 
followed by additional cis-meQTL calculations was used to estimate the influence of the first ten PCs 
to P-value inflation. The successive addition of PCs led to a very moderate increase of λ only. The 
lambda median for meQTL analysis (CpG) varied from 1.111 to 1.118. In conclusion, I can state that 
the first ten PCs do not include potential hidden factors which led to a substantial decrease of 
inflation in cis and that models can be considered robust. 
2.5.4 Imprinting methylation QTL (imeQTL) analysis in blood cells 
I used a novel approach to identify meQTLs with a Parent-of-Origin (PofO) bias. Parent-offspring trios 
with GGE were used for the dissection of differentially methylated parental genomic regions. imeQTL 
analysis in 269 parent-offspring trios was performed using gender, age of blood withdrawal, cell-type 
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composition (6 levels), month of methylotyping (4 of 5 levels) and origin as cofactors. Gender, age of 
blood withdrawal, cell-type composition, month of methylotyping and origin of sample are known 
confounders with impact on the general CpG methylome (Zhang et al. 2010). Cofactor origin included 
the different European countries (or countries with European ancestry) from where parent-offspring 
trios were recruited. The cofactors were AUS (Australia) + central Europe (Denmark & Germany) + IT 
(Italy) + TR (Turkey). Existence of additional unknown confounders with general impact on DNA 
methylation was investigated by PCA on linear regression gender/age/cell-type composition/month 
of methylotyping/origin residuals. PCAs were calculated using prcomb (stats R-package) on residuals 
of known confounders generated by lm (stats R-package). No PC was added as additional cofactor in 
imeQTL analysis as the proportion of variance remained steady across PCs and hence it can be 
assumed that the PCs have no general impact on DNA methylation; model for imeQTL analysis signal 
~ gender + age of blood withdrawal + cell-type composition + month of methylotyping + origin. 
With trios, by analyzing parent and child genotypes, rules of Mendelian inheritance allow parental 
origin of SNP alleles in the child to be defined, as long as at least one member of the trio is 
homozygous. Three cis-association tests were performed to determine the parental origin and to test 
PofO specific association for a SNP: i) an association study using only maternally inherited SNPs, ii) an 
association study using only paternally inherited SNPs, and iii) a comparison of the frequencies of the 
two classes of reciprocal heterozygote in which parental origin is reversed (AMAT/BPAT vs. APAT/BMAT; 
Garg et al. 2012). The method is summarized in Figure 2-4. 
 
Figure 2-4: Determination of parental origin and PofO specific association testing for a hypothetical SNP. 
A) & B) Assignment of allele parental origin at a given SNP (alleles A and B): the homozygous mother can only contribute 
allele A to her offspring (MAT, pink), and thus child’s B allele must be paternally inherited (PAT, blue). C) Standard 
association study between SNP genotypes and quantitative trait compared to the proposed scheme, which considers the 
parental origin of the inherited SNPs present in the child (Figure adapted from Garg et al. 2012). 
 
MATERIALS AND METHODS 
23 
 
To detect the differential paternal or maternal associations the following thresholds were defined: 1) 
one of the parental FDR corrected P-values has to be significant (FDR < 0.05) whereas the other, 
native P-value has to be non-significant (native P-value > 0.05). The difference between the maternal 
and paternal P-values had to be greater than 10-6. 
2.5.4.1 Known imprinted genes 
The definition of known imprinted genes was adopted from Fang et al. (2012). Fang and colleagues 
analyzed the methylome for a diverse set of human cell-types, including cultured and uncultured 
differentiated cells, embryonic stem cells and induced pluripotent stem cells to generate a genomic 
landscape of human allele-specific DNA methylation (Table 2-4). Validated imprinting regions were 
double-checked and ensured by using the information repository of mammalian imprinted genes, 
MetaImprint (Wei et al. 2014). 
 
Table 2-4: Known imprinted clusters and associated allelically methylated regions. 
Clusters are named according to a representative gene; approximately 65 validated human imprinting genes reside in 32 
imprinted clusters were identified. In total, 21 of the clusters contained validated allelically methylated region (AMRs) in four 
of five uncultured cells. Columns also indicate whether the selected representative AMR was previously identified, and 
whether it is a known imprinted control region (ICR). 
Imprinting 
Cluster 
hg19 location Size (kb) Uncultured Previously 
identified 
Known 
ICR 
Total 
human 
DIRAS3 chr1:68515537-68517691 2154 5 Yes Yes 19 
NAP1L5 chr4:89617864-89619549 1685 5 Yes Yes 21 
FAM50B chr6:3848745-3850911 2166 4 Yes Yes 12 
PLAGL1/HYMAI chr6:144327845-144330191 2346 4 Yes Yes 18 
DDC/GRB10 chr7:50849470-50851331 1861 4 Yes Yes 19 
SGCE/PEG10 chr7:94284018-94289851 5833 5 Yes Yes 22 
MESTIT1/MEST chr7:130129559-130133682 4123 5 Yes Yes 22 
KCNK9 chr8:141108018-141111481 3463 5 Yes Yes 20 
FANK1 chr10:127584249-127588031 3782 5 Yes Yes 18 
INS-IGF2-H19 chr11:2016476-2024739 8263 5 Yes Yes 20 
KCNQ1OT1 chr11:2719386-2722440 3054 5 Yes Yes 21 
RB1 chr13:48890275-48895948 5673 5 Yes Yes 7 
DLK1/MEG3 chr14:101290239-101295152 4913 3 Yes Yes 5 
SNRPN/SNURF chr15:25199298-25202152 2854 5 Yes Yes 22 
ZNF597,NAA60 chr16:3492777-3494769 1992 5 Yes Yes 22 
ZIM2/PEG3 chr19:57348719-57353128 4409 5 Yes Yes 12 
PSIMCT-1/HM13 chr20:30134590-30135902 1312 5 Yes Yes 20 
BLCAP/NNAT chr20:36148274-36151269 2995 5 Yes Yes 14 
L3MBTL chr20:42142223-42144439 2216 4 Yes Yes 19 
GNAS chr20:57414794-57486250 71456 5 Yes Yes 22 
TCEB3C chr18:44548657-44550534 1877 4 Yes Yes 11 
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2.6 Exploration of the genomic features of QTL analyses 
2.6.1 Genomic distribution of cis-meQTLs 
To explore the distribution of methylated sites associated with cis-meQTLs 12 chromatin state 
annotations in a B-lymphoblastoid cell line from the blood of a Caucasian female donor (GM12878; 
Ernst & Kellis 2010) were used. Ernst et al. (2011) distinguished six broad classes of chromatin states, 
which are referred to as promoter, enhancer, and insulator, as well as transcribed, repressed and 
inactive states. Within these, active, weak and poised promoters differ in expression level, strong and 
weak candidate enhancers differ in expression of proximal genes, and strongly and weakly 
transcribed regions also differ in their positional enrichments along transcripts. Polycomb-repressed 
regions differ from heterochromatin and repetitive states (Ernst et al. 2011). 
2.6.2 Enrichment analysis of cis-meQTLs and cis-eQTLs 
The enrichment analyses were performed using the R-package goseq, which allows selection-
unbiased testing for category enrichment amongst differently expressed or methylated genes. Any 
category may be tested using goseq. The following gene-sets, compiled by their expression in brain 
and their involvement in neuropsychiatric disorders, were used: i) brain expressed genes (N = 8,852; 
Pinto et al. 2014), ii) genes involved in neurodevelopmental disorders (N = 1,689; Krumm et al. 2013), 
iii) genes involved in autism spectrum disorder (N = 1,559; Uddin et al. 2014), and iv) susceptibility 
genes (N = 1,200) at GWAS loci published in the NHGRI GWAS catalog (P < 1 x 10-6; Welter et al. 
2014). A correction for the numbers of CpG sites located in different classes of genes according to 
Geeleher et al. (2013) was performed. goseq used CpG counts as bias data. For calculating the P-
values the Wallenius approximation was used. The name of the category and the P-value for the 
associated category being over represented amongst differentially methylated genes was 
documented. 
 
2.7 Exploration of the role of QTL-associated rSNPs in common neuropsychiatric 
disorders 
Five filtering steps were carried out to explore whether regulatory SNPs (rSNPs) affecting 
transcription factor binding sites (TFBS) underlie both the cis-acting QTLs (meQTLs and eQTLs) and 
the regional GWAS hits. The step-wise filtering procedures included: 1) positional screening of cis-
QTLs close by (1 Mbps window) the lead SNPs of GWAS hits (P < 5 x 10-8); 2) dissection of those SNP-
pairs (cis-QTL-SNP / GWAS-SNP) showing a LD-relationship with r2 > 0.5; 3) extension of the 
candidate rSNPs by capturing all SNPs in LD r2 > 0.8 with the GWAS lead SNP; 4) prioritization of 
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potential rSNPs affecting TFBS by assessing the allelic alteration of their binding affinity using the 
GWAS3D software tool (http://jjwanglab.org/gwas3d, Li et al. 2013); and 5) quantitative estimates of 
pathogenic effects across a wide range of functional categories based on i) the combined annotation 
dependent depletion score (CADD score, Kircher et al. 2014), and ii) the GERP++ score assessing 
evolutionary sequence conservation (Davydov et al. 2010) implemented in the SNP annotation tool 
SNiPA (http://snipa.helmholtz-muenchen.de/snipa/, Arnold et al. 2014).  
The detected transcription factors (TFs) all belong to TRANSFAC (TRANScription FACtor database) 
which is a database on eukaryotic transcriptional regulation comprising data on TFs, their target 
genes and regulatory binding sites (Matys 2003). 
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3. RESULTS 
My analyses addressed the following objectives: 
1) Identification of rSNPs quantitatively influencing CpG methylation and mRNA expression in 
fresh frozen hippocampal brain tissue. 
2) Delineation of a genome-wide meQTL map in fresh frozen hippocampal brain tissue and 
blood cells, offering the dissection of accessible biomarkers. 
3) Genome-wide assessment of imeQTLs to identify loci that are prone for susceptibility effects 
by their Parent-of-Origin PofO dependent monoallelic expression. 
4) Generation of a genome-wide eQTL map in fresh frozen hippocampal brain tissue and 
delineation of methylation-driven gene expression. 
5) Identification of rSNPs involved in common brain disorders. 
Genome-wide methylation and expression analyses were performed in fresh frozen hippocampal 
brain tissue of 115 European (descent) patients with resistant mesial temporal lobe epilepsy (mTLE). 
These analyses were meant to gain fundamental insights into epigenetic regulation in human 
hippocampal brain tissue and to dissect those epigenetic alterations involved in common 
neuropsychiatric disorders. For this goal, individual high-density SNP genotypes were correlated with 
both (i) the individual quantitative methylation states of 362k CpG sites assessed by the Human 
Methylation450 array (HM450) and (ii) the individual expression level of 31k gene transcripts using 
the Human HT-12 v3 array. To delineate accessible epigenetic biomarkers, genome-wide maps of 
meQTLs were also generated in whole blood cells from 496 German population controls using the 
same 362k HM450 CpG sites.  
The significance threshold applied throughout this study refers to a standard FDR threshold < 0.05 
based on all examined SNP/CpG or SNP/mRNA pairs. In the following, a cis-meQTL or cis-eQTL will 
refer to the most associated SNP/CpG or SNP/mRNA pair within the 1 Mbps windows flanking the 
target CpG or target mRNA probe. Trans-meQTLs or trans-eQTLs will refer to all SNP/CpG or 
SNP/mRNA pairs outside the 1 Mbps windows flanking the target CpG or target mRNA probe. 
 
3.1 Methylation QTL analyses 
3.1.1 Cis-meQTL analysis in hippocampal brain tissue 
The meQTL analysis examined the influence of cis-acting genetic variations on the quantitative state 
of CpG methylation. After stringent quality control, 362,722 CpGs and 643,195 LD-pruned SNPs were 
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correlated for cis-meQTL analysis, resulting in 1.75 x 108 tests corresponding to a nominal 
significance threshold of P = 2.95 x 10-5 at a FDR of 5%. At the FDR threshold of 5%, 19,954 (5.5%) out 
of 362,722 CpG sites account for significant cis-acting meQTLs (P-value range = 1.99 x 10-59 to 2.95 x 
10-5, Figure 3-1). A QQ-plot of the CpG methylation in 115 hippocampal brain tissue samples is shown 
in Appendix, Figure 6-1. 
 
Figure 3-1: Manhattan plot for cis-meQTLs identified in hippocampal brain tissue samples. 
The x-axis shows the genomic position of CpGs on chromosomes 1 to 22 (NCBI built 37.3, hg19); the y-axis shows the 
negative log10 of the P-value per SNP/CpG pair. The red line represents the threshold for significant cis-meQTLs with FDR < 
0.05. The genes of the 20 most significant cis-meQTLs (shown in Table 3-4) are highlighted. 
 
In total, 13,355 out of 19,954 cis-meQTLs were located intragenic of 7,827 Ensembl genes (hg19). For 
1,934 cis-meQTL CpGs a signal with two or more different gene transcripts was observed, while 6,599 
cis-meQTLs could not be localized to an Ensembl gene annotation. 11,253 SNPs showed cis-
association with two or more CpG sites. The positions of SNPs with significant cis-meQTLs were 
preferentially located near the CpG sites, 76% within a range of < 150 kb. 
3.1.1.1 Genomic features associated with cis-meQTLs 
Previous studies have shown that SNPs are weakly correlated with the methylation status of CpG 
islands (Bock et al. 2007; Gibbs et al. 2010). Consistently, cis-meQTLs in hippocampal brain tissue 
were found to be more likely outside of CpG islands than within (as defined in Gardiner-Garden & 
Frommer 1987). While 55% of 362k CpG sites are within a CpG island, only 23% of the CpG sites of a 
significant meQTL for mTLE patients were in islands (P < 2.2 x 10-16). These results focused on CpG 
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islands themselves without considering CpG island shores (0-2 kb from CpG island) and CpG island 
shelves (2-4 kb from CpG island). 
Exploration of the cis-meQTLs in gene-centric regions revealed a moderate enrichment in the 
TSS1500 region encompassing the regulatory 5´-region 1500 bps upstream from the transcription 
start site (TSS), compared to the distribution of all quality-filtered 362k CpGs (P = 4.41 x 10-3; Table 3-
1 & Figure 3-2). For the other genomic regions a depletion of sites associated with meQTLs were 
found. The findings revealed a particular accumulation of cis-meQTLs in the gene-centric region 
TSS201-TSS1500. In total, 3,055 (8.45%) cis-meQTLs were found in the TSS201-TSS1500 region 
compared to 3.6% of all 362k CpG sites (P = 7.72 x 10-61). 
Table 3-1: Distribution of meQTLs within different gene-centric regions in hippocampal brain tissue. 
The proportion of all quality-filtered 362,722 CpGs in gene-centric regions, as specified by Illumina is shown. Pearson's Chi-
squared test with Yates' continuity correction was used to calculate the distribution of 19,954 cis-meQTLs (FDR < 0.05) in 
different gene-centric regions in hippocampal brain tissue compared to all 362k CpG sites. Red colored background indicates 
depletion, green colored background an enrichment of meQTLs compared to all 362k CpGs. TSS200 & TS1500, promoter 
regions were divided into two bins of 200 bps and 1,500 bps blocks upstream of the TSS.  
Illumina Group All, 362,722 CpGs cis-meQTL, brain P-values, cis-meQTL, brain 
1st Exon 4.88% 3.02% *** 4.70E-36 
3'UTR 3.72% 3.16% **   1.60E-05 
5'UTR 9.15% 7.16% *** 9.45E-24 
Gene Body 34.06% 34.27%        5.40E-01 
TSS200 10.98% 6.86% *** 1.07E-81 
TSS201-1500 14.62% 15.31% *     4.41E-03 
Intergenic regions 22.59% 30.22%*** 2.50E-155 
Chi-square test: ***P < 10
-50
; **P < 10
-5
; *P < 0.05 
 
 
Figure 3-2: Functional localization of genomic regions of meQTLs in hippocampal brain tissue. 
Distribution of different genomic regions for the significant 19,954 meQTLs obtained from hippocampal brain tissue. 
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3.1.1.2 Enrichment analysis 
To investigate the biological function of the obtained cis-meQTL signals I looked for an enrichment of 
gene-sets compiled by their expression in brain and their involvement in neuropsychiatric disorders. 
The gene-sets included brain expressed genes (N = 8,852; Pinto et al. 2014), genes involved in 
neurodevelopmental disorders (N = 1,689; Krumm et al. 2013) and autism spectrum disorder (N = 
1,559; Uddin et al. 2014). In addition, susceptibility genes (N = 1,200) at GWAS loci published in the 
NHGRI GWAS catalog (P < 1 x 10-6, Welter et al. 2014) were examined for the following common 
neuropsychiatric disorders: Alzheimer’s disease, attention-deficit hyperactivity disorder, autism, 
bipolar disorder, epilepsy, major depressive disorder, migraine, nicotine dependence, Parkinson’s 
disease and schizophrenia. This gene-set will further be referred as Brain-Disorder-GWAS gene-set. 
Because functional categories are biased by differing CpG contents of the gene-sets, a CpG bias 
correction was applied. Therefore, the number of CpG sites located in different classes of genes was 
adjusted according to the procedure recommended by Geeleher et al. (2013). The meQTLs in 
hippocampal brain tissue were significantly enriched in the Brain-Disorder-GWAS gene-set (P = 5.79 x 
10-4) and in the gene-set previously implicated in neurodevelopment disorders (P = 0.04). No 
significant enrichment was observed for brain-expressed and for autism spectrum disorder genes 
after correcting of the CpG bias (Table 3-2). The significance of these results was determined 
empirically using sample randomization of 1,000 randomly distributed genes. 
Table 3-2: Gene-set enrichment analyses of cis-meQTLs in hippocampal brain tissue. 
Enrichment analyses performed in hippocampal brain tissue samples. The analyses applied a correction of the number of 
CpG sites per gene, respectively. For each category a P-value is given for an enrichment of the compiled gene-set category. 
Category Overrepresented P-value 
Brain-Disorder-GWAS Genes (N = 1,200) 5.79E-04 
Neurodevelopment Genes (N = 1,689) 3.90E-02 
Autism Spectrum Disorder Genes (N = 1,559) 6.12E-01 
Brain Expressed Genes (N = 8,852) 1.00E+00 
 
3.1.1.3 Comparison of cis-meQTLs in hippocampal brain tissue and top cis-meQTLs 
I compared cis-meQTL findings obtained from recent studies analyzing cis-meQTLs with quality-
filtered 362k CpGs (Gibbs et al. 2010; Zhang et al. 2010; Numata et al. 2014; Smith et al. 2014; for an 
overview on studies that are frequently mentioned for comparison reasons, please refer to Table 6-2 
in Appendix). Notable, all comparable meQTL studies assessed cis-methylation levels of postmortem 
brain tissue and peripheral blood cells with the Infinium HumanMethylation27 BeadChip (HM27). In 
total, 69% of the cis-meQTLs generated by Gibbs et al. (2010), 71% of the cis-meQTLs generated by 
Zhang et al. (2010), 67% of the cis-meQTLs generated by Numata et al. (2014), and 77% of the cis-
meQTLs generated by Smith et al. (2014) could be identified in the 362k CpGs (Table 3-3). Overall, 
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66% of the cis-meQTLs generated by the four previous studies were also identified as significant cis-
meQTLs in the present study. 
Table 3-3: Overlaps with comparable human meQTL studies. 
Epigenetic study Cell-type or tissue studied Overlap with 362k CpGs 
Gibbs et al. (2010) Postmortem brain tissue 69% (615 out of 887) 
Zhang et al. (2010) Postmortem brain tissue 71% (1,446 out of 2,046) 
Numata et al. (2014) Postmortem brain tissue 67% (2,427 out of 3,612) 
Smith et al. (2014) Whole Blood & postmortem brain tissue 77% (710 out of 926) 
 
A major aim of the present meQTL study was a comprehensive map of meQTL findings of all quality-
checked 362k CpGs for 115 hippocampal brain tissue samples and 496 blood cell samples in a 
publically accessible database. These databases will be reported in context with the publication of 
this study (manuscript in preparation). 
The 20 most significant cis-meQTLs for hippocampal brain tissue are shown in Table 3-4. Additionally, 
FDR values of the cis-meQTLs for the respective CpG site in blood cells are listed.  
  
 
Table 3-4: Top hits of meQTLs in hippocampal brain tissue. 
CpG Chr CpG Pos Gene Symbol meQTL SNP SNP Pos FDR, brain FDR, blood 
cg07796016 1 152779584 LCE1C(0.5k) rs7524281 152783255 3.48E-51 2.29E-202 
cg09316607 10 1511024 ADARB2 rs1533486 1511786 5.52E-50 > 5.00E-02 
cg15652532 2 30669759 LCLAT1(0.3k) rs4952148 30777908 1.12E-49 3.02E-240 
cg04993605 1 28573052 ATPIF1 rs2938867 28515292 1.92E-45 > 5.00E-02 
cg08308162 16 8889244 PMM2 rs45515994 8876845 1.28E-44 5.29E-21 
cg24657347 2 20261756 AC098828.2(1.9k) rs7570953 20255015 6.25E-44 > 5.00E-02 
cg06917450 1 38156652 C1orf109 rs768659 38162707 6.51E-43 1.67E-189 
cg21717724 9 123604514 PSMD5-AS1 rs3793638 123582697 1.15E-42 2.82E-159 
cg02375585 6 33091111 HLA-DPB2 rs114476417 33094663 6.13E-42 1.22E-39 
cg23649088 2 200775458 AC073043.1 rs10180850 200747690 2.94E-41 3.29E-202 
cg12454169 2 30669597 LCLAT1(0.5k) rs4952148 30777908 3.91E-41 1.45E-196 
cg09496634 16 87712353 JPH3 rs888652 87712366 7.60E-41 2.41E-119 
cg19766460 21 43528205 C21orf128 rs2051401 43530856 9.01E-41 8.15E-238 
cg24441899 7 4244372 SDK1 rs57656159 4244666 3.41E-40 9.79E-103 
cg14418922 10 70824840 SRGN(23.0k) rs17558246 70851873 4.79E-40 1.65E-217 
cg19825371 17 79454562 ACTG1(22.4k) rs62075991 79459113 7.16E-40 1.98E-126 
cg18795169 1 18902165 RP1-8B22.2(19.7k) rs2745311 18904033 2.85E-38 8.01E-114 
cg14440550 9 136131118 ABO rs8176751 136131022 3.07E-38 2.16E-139 
cg01290755 12 129554587 TMEM132D(1.7k) rs11060115 129554644 3.07E-38 5.92E-153 
cg07673080 2 240241154 HDAC4 rs12476996 240257894 7.23E-38 2.62E-133 
Abbreviations: CpG, Illumina annotation of the CpG dinucleotide; Chr, chromosome; CpG Pos, cytosine base-pair position of CpG site; Gene Symbol, gene which contains the CpG site; meQTL SNP 
brain, SNP of the most significant meQTL in hippocampal brain tissue; SNP Pos brain, base-pair position of SNP in hippocampal brain tissue; FDR brain & blood, most significant FDR for a SNP-CpG 
pair in hippocampal brain tissue samples and in blood cell samples. All annotations refer to genome build hg19. 
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3.1.1.4 Neurodevelopmental candidate genes of cis-meQTLs 
Some of the most significant cis-meQTLs were identified in genomic regions of several high-ranking 
candidate genes for neurodevelopmental disorders: ADARB2 (Pmin = 6.33 x 10
-58), HDAC4 (Pmin = 1.62 x 
10-44), NAPRT1 (Pmin = 1.61 x 10
-39), MAD1L1 (Pmin = 8.35 x 10
-29), PTPRN2 (Pmin = 1.67 x 10
-26), and 
RIMBP2 (Pmin = 2.32 x 10
-24; Table 3-5). 
Table 3-5: Significant cis-meQTLs of high-ranking candidate genes in hippocampal brain tissue.  
CpG Chr CpG Pos Gene 
Symbol 
meQTL SNP SNP Pos FDR Rank cis-
meQTL 
cg09316607 10 1511024 ADARB2 rs1533486 1511786 5.52E-50 2 
cg07673080 2 240257894 HDAC4 rs12476996 240257894 7.23E-38 29 
cg17524265 8 144659883 NAPRT1 rs9657360 144676862 3.20E-33 61 
cg13165778 7 1952518 MAD1L1 rs6950151 1953521 3.52E-23 247 
cg24764310 7 157512201 PTPRN2 rs11762822 157507684 4.70E-21 351 
cg20111978 12 130959558 RIMBP2 rs6486542 130952209 4.54E-19 481 
Abbreviations: Rank cis-meQTL, position of the significant cis-meQTL compared to all detected cis-meQTLs; other 
abbreviations see Table 3-4. 
 
3.1.2 Comparative cis-meQTL analysis of brain cells and whole blood cells 
To discover accessible epigenetic biomarkers and to test for tissue specificity in meQTL analyses, a 
genome-wide map of cis-meQTLs were also generated in whole blood cells from 496 German 
population controls using the same 362k HM450 CpG sites. After stringent quality control, 362,722 
CpGs and 539,936 LD-pruned SNPs were correlated for cis-meQTL analysis in blood cell samples, 
resulting in 1.60 x 108 tests corresponding to a nominal significance threshold of P = 4.40 x 10-4 at a 
FDR of 5%. At the FDR threshold of 5%, 108,628 (30%) out of 362,722 CpG sites were identified as cis-
meQTLs (P-value range = 2.23 x 10-308 to 4.40 x 10-4). A QQ-plot of the meQTL analysis in blood cell 
samples is shown in Appendix, Figure 6-1. 
In total, more than 65% of the significant cis-meQTLs in hippocampal brain tissue were also found in 
blood cells. Overall, 12,974 out of 19,954 CpGs with significant meQTLs in hippocampal brain tissue 
represent also meQTLs in blood cells. Accordingly, a moderate correlation of the significant cis-
meQTL results in the hippocampal brain tissue and the cis-meQTL results in blood cells (Spearman’s 
Rank coefficient = 0.416; Figure 3-3) was observed. 
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Figure 3-3: P-value scatter plot of hippocampal brain tissue and blood cells. 
The linear correlation between 115 hippocampal brain tissue samples and 496 blood cell samples is shown. The negative 
log10 of the P-value per SNP/CpG pair is plotted. 
 
Cis-acting meQTLs with the best value per CpG at different significance thresholds for hippocampal 
brain tissue as well as for blood cells are given in Table 3-6. 
Table 3-6: Frequency of cis-meQTLs for different significance thresholds for hippocampal brain tissue and blood cells. 
Threshold Brain cis FDR Blood cis FDR 
Value < 5.00E-02 19,954 108,628 
Value < 1.00E-10 1,899 24,346 
Value < 1.00E-20 378 13,908 
Value < 1.00E-30 84 9,177 
Value < 1.00E-40 19 6,548 
Value < 1.00E-50 1 4,891 
 
Whereas the majority of cis-meQTLs seems to be consistent across tissues – 65% of the significant 
meQTLs in hippocampal brain tissue represent meQTLs in blood cells –also hippocampal brain tissue-
specific meQTLs were observed. The 10 most significant tissue-specific cis-meQTLs for hippocampal 
brain tissue are shown in Table 3-7. An extra column also indicates the non-significant P-values of the 
respective CpG sites of the cis-meQTLs in blood cells. 
  
 
Table 3-7: Brain tissue-specific cis-meQTLs not found in blood cells. 
CpG Chr CpG Pos Gene Symbol meQTL SNP SNP Pos FDR, brain Rank cis-meQTL P-value, blood 
cg09316607 10 1511024 ADARB2 rs1533486 1511786 5.52E-50 2 1.27E-03 
cg04993605 1 28573052 ATPIF1 rs2938867 28515292 1.92E-45 5 4.46E-04 
cg24657347 2 20261756 AC098828.2(1.9k) rs7570953 20255015 6.25E-44 9 1.54E-03 
cg13560919 6 33536144 BAK1(4.2k) rs17627049 33537802 6.06E-34 52 2.14E-03 
cg05315633 6 168628719 RP11-503C24.2(1.5k) rs73028658 168623545 2.80E-33 60 7.16E-03 
cg23020514 14 103360112 TRAF3 rs7147331 103380208 1.97E-31 75 1.13E-03 
cg05431684 11 130781542 SNX19 rs73028875 130780595 9.17E-30 96 7.88E-04 
cg16307866 4 7129517 RN7SKP36(15.4k) rs4689604 7129556 1.03E-29 98 3.11E-03 
cg07744270 11 64186719 AP003774.5(1.1k) rs10897503 64186979 1.11E-29 99 9.58E-04 
cg13144783 3 46249795 CCR3 rs2201150 46258902 1.06E-28 110 1.14E-03 
Abbreviations: P-value, blood, refers to the most significant P-value for a SNP-CpG pair in blood cell samples (FDR < 0.05); other abbreviations see Table 3-4. All annotations refer to genome build 
hg19. 
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3.1.2.1 Genomic distribution of cis-meQTLs 
I compared the distribution of methylated sites associated with cis-meQTLs of all assayed 362k CpG 
methylation sites in B-lymphoblastoid cells (GM12878) and further compared the distribution of 
significant cis-meQTL associated CpGs between hippocampal brain tissue and blood cells. A strong 
significant depletion of sites associated with meQTLs at active promoters (P = 7.17 x 10-101 for brain 
meQTLs and P < 10-300 for blood meQTLs), as well as a moderate enrichment at weak promoters 
(P = 7.16 x 10-3 for brain meQTLs and P = 2.3 x 10-4 for blood meQTLs) was found. In addition, a 
relative enrichment of meQTLs at insulators (P = 1.72 x 10-26 for brain meQTLs and P = 7.07 x 10-91 for 
blood meQTLs) and at enhancers (P = 4.63 x 10-12 for brain meQTLs and P < 10-250 for blood meQTLs) 
were found. In particular, these results show that the distribution of the meQTLs obtained from 
blood cells display a similar distribution as those found in hippocampal brain tissue. An overlap of 
90% of meQTL associated CpGs between hippocampal brain tissue and blood cells (Table 3-8 & Figure 
3-4) was observed. 
Table 3-8: Genomic distribution of cis-meQTL associated CpGs in hippocampal brain tissue and blood cells. 
Specified genomic features from cell line GM12878 were counted for all quality-filtered 362,722 CpGs. Pearson's Chi-squared 
test with Yates' continuity correction was used to calculate the distribution of the genomic features of CpGs of significant cis-
meQTLs (FDR < 0.05) in hippocampal brain tissue and blood cell versus all 362k CpG sites. The last column represents the 
concordance of meQTL associated CpGs within the genomic feature between hippocampal brain tissue and blood cells. Red 
colored background indicates depletion, green colored background an enrichment of meQTL associated CpGs versus all 
CpGs.  
Cell-type (GM12878) All, 
362k CpGs 
cis-meQTL, brain P-values, 
cis-meQTL, 
brain 
cis-meQTL, 
blood 
Brain vs. 
blood 
Active Promoter 19.89% 11.81% **** 7.17E-101 12.30% **** 96% 
Weak Promoter 6.84% 7.22% *        7.16E-03 7.08% *        98% 
Poised Promoter 4.35% 3.57% **      5.05E-09 3.94% **      91% 
Strong Enhancer 4.06% 5.07% **      4.63E-12 5.94% ****  85% 
Weak Enhancer 6.10% 6.86% **      1.51E-06 7.36% ***    93% 
Insulator 1.62% 2.64% **      1.72E-26 2.27% ***    86% 
Transcriptional Transition 1.15% 0.99% *        6.45E-03 1.17%             85% 
Transcriptional Elongation 5.40% 3.87% **      7.49E-23 4.08% ***    95% 
Weak Transcribed 9.49% 10.91% **      2.45E-19 9.77% *        90% 
Polycomb Repressed 10.68% 11.27% **      8.95E-08 12.21% ***    92% 
Heterochromatin 30.21% 35.44% ***    6.40E-55 33.63% ***    95% 
Repetitive/CNV 0.20% 0.36% **      2.47E-06 0.25% **      69% 
Missing Type 0.01% 0.01%            3.70E-01 0.01%            100% 
Chi-square test: ****P < 10
-100
; ***P < 10
-50
; **P < 10
-5
; * P < 0.05 
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Figure 3-4: Functional localization of CpGs in GM12878. 
Distribution of different regulatory annotations in GM12878 for A) all 362,722 CpGs, B) the significant 19,954 meQTLs 
obtained from hippocampal brain tissue, and C) the significant 108,628 meQTLs obtained from blood cells. 
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3.1.3 Trans-meQTL analysis in hippocampal brain tissue 
After stringent quality control, 362,722 CpGs and 643,195 LD-pruned SNPs were correlated for trans-
meQTL analysis, resulting in 2.33 x 1011 tests corresponding to a nominal significance threshold of 
P = 1.93 x 10-9 at a FDR of 5%. In addition to the CpG quality filters applied for meQTL analysis, a 
more stringent filter was used to sort out CpG probes that show cross-hybridization at other genomic 
locations (Zhang et al. 2014) and may lead to ambiguous CpG methylation states. Accordingly, trans-
meQTLs analysis was carried out with 268,397 CpGs. At the FDR threshold of 5%, 3,927 out of 
268,397 CpG sites account for significant trans-acting meQTLs (P-value range = 2.93 x 10-38 to 1.93 x 
10-9). 
As in previous studies comparing QTL P-value distributions in cis and trans, more strong associations 
in cis were found (Gibbs et al. 2010; Gamazon et al. 2013; Ramasamy et al. 2014). In total, 348 trans-
meQTL SNPs were significantly associated with methylation levels of two or more genes. Among 
those, eight “master regulatory loci” with significant simultaneous impact on methylation level of 
four or more genes in trans were identified (Figure3- 5). 
To eliminate long-range (>± 1 Mbps) cis-acting meQTLs, it was checked whether trans-CpGs and 
markers were located on the same chromosome. This pattern was observed for 189 trans-meQTLs, 
but the trans-markers were more than 10 Mbps away from the CpG sites. Thus, for these SNPs, the 
effect on the regulation of genes in trans are unlikely to result from long-range cis-relationships. 
 
Figure 3-5: Circos plot of 115 hippocampal brain tissue for trans-meQTLs. 
Criteria for plotting trans-meQTLs: CpG to SNP distance > 10 Mbps, stack size ≥ 4 CpGs per SNP and FDR corrected P-value 
(P < 0.05), 1 Mbps frame in 100k sliding window. The -log10 P-values are plotted at CpG position. 
 
RESULTS 
38 
 
Except for two SNPs (rs114267096 and rs1273196), all trans-acting meQTL SNPs with simultaneous 
impact on the regulation of four or more genes were not significantly associated with the 
methylation of a gene located in cis in the underlying data. However, the effects in trans were barely 
significant; it is difficult to cover robust trans-meQTL findings. 
Comparison of trans-meQTL results with other studies testing trans-associations was sparsely useful. 
Comparable studies assessed methylation levels of postmortem brain tissue with the HM27 
BeadChips and utilized different CpG quality filters (Gibbs et al. 2010; Zhang et al. 2010; Numata et 
al. 2012). A table with the eight master regulatory loci with significant simultaneous impact on 
methylation level of four or more genes in trans can be found in Appendix, Table 6-3. 
3.1.4 Imprinting methylation QTL analysis in blood 
In total, blood cell DNA samples of 269 parent-offspring trios with GGE were investigated to screen 
for differentially methylated parental genomic regions. Screening for imeQTLs was performed by 
comparing CpG methylation states of GGE trio offspring with nearby reciprocal heterozygote SNP 
genotypes of inverse parental origin (AMAT/BPAT vs. APAT/BMAT; Garg et al. 2012). Thus, any difference in 
the CpG methylation state detected between these two groups strongly suggests an underlying PofO 
effect. To specify the parental methylation status of an imeQTL, association analyses using only i) 
maternally inherited and ii) paternally inherited SNP alleles were carried out. The predominant 
parental CpG methylation state is indicated by the segregation of the alleles. 
After stringent quality control, 362,722 CpGs and 886,110 LD-pruned SNPs were correlated for the 
imeQTL analysis, resulting in 1.92 x 108 tests corresponding to a nominal significance threshold of P = 
1.68 x 10-7 at a FDR of 5%. At the FDR threshold of 5%, 177 out of 362,722 CpG sites were identified 
as autosomal imeQTLs (P-value range = 3.47 x 10-46 to 1.68 x 10-7, Figure 3-6). QQ-plots of the CpG 
methylation in parent-offspring trios are shown in Appendix, Figure 6-2 and Figure 6-3. 
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Figure 3-6: Manhattan plot for cis-imeQTLs of 269 trio offspring. 
The x-axis shows the genomic position of CpGs on chromosomes 1 to 22 (NCBI built 37.3, hg19); the y-axis shows the 
negative log10 of the P-value per SNP/CpG pair. The red line represents the significance threshold of P < 1.68 x 10
-7
 
corresponding to a FDR of 5%. Red dots and in red highlighted gene names indicate CpGs in validated imprinted regions (P < 
1.68 x 10
-7
). In blue highlighted gene names indicate CpGs in novel imprinted regions which are shown in Table 3-9. 
 
Genome-wide screening of imeQTLs revealed significant imeQTLs for 177 CpGs at 31 genomic loci 
(P < 1.68 x 10-7). Altogether, nine known and 22 potentially novel imprinted regions were identified 
and subsequently specified for their predominant parental methylation state. In total, 29% of the 
imeQTLs (N = 52) reside in nine known imprinting regions (Fang et al. 2012; Wei et al. 2014). The top-
ranked imprinted loci were observed in the region 4q22.1 at the known imprinted HERC3/NAP1L5 
locus (Pmin = 3.47 x 10
-46), at chromosome 20q11.23 at the known imprinted NNAT/BLCAP locus 
(Pmin = 5.41 x 10
-22), and at a novel locus on chromosome 3p21.1. The 3p21.1 locus harbors GWAS 
candidate regions for among others bipolar disorder and major depressive disorder including the 
genes NISCH/STAB1 (Pmin = 6.56 x 10
-39), ITIH3 (Pmin = 9.24 x 10
-32) and GNL3 (Pmin = 1.71 x 10
-26). 
The 10 most significant imeQTLs including several high-ranking candidate genes emphasized for 
neurodevelopmental disorders are shown and listed in Table 3-9. The most significantly imeQTLs 
exhibited a combination of both; PofO and allele-specific effects on CpG methylation. The delineation 
of the parental methylation status of an imprinted CpG and the quantification of the allele-specific 
meQTL effect is shown exemplary in Figure 3-7 for two top imeQTL signals; at chromosome 3p21.1 
(NISCH) and at chromosome 20q11.23 (NNAT/BLCAP). 
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Table 3-9: Top 10 imeQTLs and specification of their preferential parental expression. 
CpG Chr CpG Pos Gene Symbol imeQTL SNP SNP Pos FDR (het) Impr locus Meth 
allele 
cg26065870 3 52522591 NISCH rs409803 52443280 4.21E-31 Novel Mat 
cg18182844 3 52828292 ITIH3(0.5k) rs409803 52443280 4.45E-24 Novel Mat 
cg00447581 3 52724578 GNL3 rs409803 52443280 6.58E-19 Novel Mat 
cg07598930 3 52233294 ALAS1 rs409803 52443280 1.34E-12 Novel Mat 
cg01026744 4 89619053 HERC3/NAP1L5 rs61737091 89671721 6.68E-38 Known Pat 
cg11408952 13 48892244 RB1 rs3825417 48891836 3.84E-13 Known Pat 
cg02273647 14 45722745 MIS18BP1 rs114370731 45386388 4.12E-13 Novel Pat 
cg23757721 20 36148604 NNAT/BLCAP chr20:36159062:D 36159062 1.74E-14 Known Pat 
cg08402058 20 36148961 NNAT/BLCAP chr20:36159062:D 36159062 2.06E-14 Known Pat 
cg14765818 20 36148954 NNAT/BLCAP chr20:36159062:D 36159062 1.98E-12 Known Pat 
Abbreviations: FDR (het), FDR-value of the heterozygote test; Impr locus, indicating if the imeQTL is at a known or novel 
imprinting locus. The predominant parental CpG methylation state is indicated by the parental methylated allele identified 
by the transmission analysis (‘Meth allele’), whereas ‘Pat’ indicates the paternally-derived allele and ‘Mat’ indicates the 
maternal-derived allele. All annotations refer to the genome build hg19. 
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Figure 3-7: Quantification of the allele-specific imeQTL effect. 
The upper plots present regional detail plots of the negative log10 of P-values of the imeQTL analysis; the x-axes show the 
genomic position of CpGs at a specific locus. Genes close to the detected association are presented as well. The lower box-
plots show the distribution of the methylation states for a specific CpG. In A) a regional detail plot of the negative log 10 P-
value for CpG cg26065870 on chromosome 3p21.1 and a box-plot of the paternally imprinted CpG cg26065870 at the NISCH 
locus is shown; in B) a regional detail plot of the negative log10 P-value for CpG cg23757721 on chromosome 20q11.23 and 
a box-plot of the maternally imprinted CpG cg23757721 at the NNAT/BLCAP locus. 
 
 
RESULTS 
43 
 
The boxplots show the distribution of the methylation states for the CpGs, respectively with respect 
to maternally and paternally inherited SNPs. The x-axis shows the genotypes of the parental origin of 
the heterozygous SNP alleles, respectively: for example in A) Gmat and Amat for maternally inherited 
SNPs and Gpat and Apat for paternally inherited SNPs. At the y-axis the methylation level, expressed as 
M-value of the CpGs is shown. The M-value ranges among +3 and -3 whereas a positive M-value 
indicates that the allele is highly methylated and therefore inactivated. An allele-specific effect was 
observed. Furthermore the observed difference between heterozygous individuals of reciprocal 
parental origin indicated a PofO effect at these loci, as these individuals showed a difference in 
methylation despite having the same genotype. 
The region of chromosome 3p21.1 is of special interest as several studies listed in the NHGRI GWAS 
catalog found genome-wide significant evidence that SNPs in this region were associated with 
various neuropsychiatric diseases including major mood disorder (composed of bipolar disorder and 
major depressive disorder), autism spectrum disorder, attention-deficit hyperactivity disorder and 
schizophrenia. Additionally, Witt and colleagues (2014) identified STAB1 as the potentially causative 
gene for bipolar disorder. This gene is located in close proximity to known mood disorder genes of 
the 3p21.1 region including PRBM1 (McMahon et al. 2010) and the NEK4-ITIH1-ITIH3-ITIH4 multigene 
region (Psychiatric GWAS Consortium Bipolar Disorder Working Group 2012). 
Further, the imeQTL results in 269 blood cell trios were compared with a recently published eQTL 
study in highly divergent mouse crosses (Crowley et al. 2015). Crowley and co-workers (2015) 
observed that classical imprinting is under genetic control and found a global allelic imbalance in 
expression favoring the paternal allele; imprinted genes were 1.5 times more likely to be expressed 
from the paternal than the maternal allele. My imeQTL results were consistent with these 
observations. A 1.8 times increased likelihood of imprinted genes to be expressed from the paternal 
than the maternal allele was observed (79 among 123 divergent parental imeQTLs were expressed 
from the paternal allele, 64%). 
In total, 138 among 177 imeQTL CpGs were located intragenic of 78 Ensembl genes (hg19). Among 
these 78 genes, eight (10%) were consistent with the imprinted genes in mouse brain reported by 
Crowley et al. (2015). Yet, half (N = 4) of the overlapping genes were in the top 55 of the 
heterozygous imprinting analysis. All overlapping genes were detected by a threshold of P < 1.68 x 
10-7 (Table 3-10). Additionally, by using the paternal-specific association analysis the GABRB3 locus 
which is known to be involved in epileptogenesis (Urak et al. 2006; Pernhorst et al. 2011) was 
detected. This locus showed evidence of association with paternally inherited alleles but no 
association with maternally inherited alleles. GABRB3 was also included in the imprinting gene list of 
Crowley et al. (2015) as a paternally expressed allele. 
  
 
Table 3-10: Eight imeQTLs with specification according to their parental expression loci consistent with Crowley et al. (2015).  
CpG Chr CpG Pos Gene Symbol imeQTL SNP SNP Pos FDR (het) Rank imeQTL Impr locus Meth allele P-value, Mat P-value, Pat 
cg01026744 4 89619053 HERC3/NAP1L5 rs61737091 89671721 6.68E-38 1 Known Pat 5.88E-04 3.55E-164 
cg23757721 20 36148604 NNAT/BLCAP chr20:36159062:D 36159062 1.74E-14 5 Known Pat 8.78E-03 4.58E-39 
cg18279536 14 101194748 DLK1 rs10144381 101173297 3.09E-16 21 Known Pat 9.29E-05 2.59E-14 
cg17696847 20 57414217 GNAS rs6070619 57383157 1.27E-05 52 Known Mat 3.24E-19 2.42E-07 
cg05260959 7 130133110 MEST rs992859 130120122 1.29E-04 64 Known Pat 1.06E-03 3.68E-17 
cg23460430 6 144329887 PLAGL1 rs55769736 144333557 1.53E-04 67 Known Pat 2.50E-03 1.56E-18 
cg27644292 15 25123287 SNRPN rs73371266 25128475 6.04E-04 80 Known Pat 5.05E-04 4.94E-22 
cg16349612 7 50849723 GRB10 rs1019002 50810582 1.85E-02 141 Known Pat 3.28E-04 3.94E-13 
Abbreviations: FDR (het), FDR-value of the heterozygote test; Impr locus, indicating if the imeQTL is at a known or novel imprinting locus. The predominant parental CpG methylation state is 
indicated by the parental methylated allele identified by the transmission analysis (‘Meth allele’), whereas ‘Pat’ indicates the paternally-derived allele and ‘Mat’ indicates the maternal-derived 
allele. All annotations refer to genome build hg19. 
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3.2 Expression QTL analyses 
3.2.1 Cis-eQTL analysis in hippocampal brain tissue 
The eQTL analysis examined the influence of cis-acting genetic variations on the quantitative state of 
mRNA gene expression using the Illumina HumanHT-12 v3 (HT12v3) array. After stringent quality 
control, 31,146 mRNA probes and 643,195 LD-pruned SNPs were correlated for cis-eQTL analysis, 
resulting in 8.46 x 106 tests corresponding to a nominal significance threshold of P = 2.10 x 10-5 at a 
FDR of 5%. At the FDR threshold of 5%, 734 (2.4%) out of 31,146 mRNA probes account for significant 
cis-acting eQTLs (P-value range = 2.34 x 10-42 to 2.10 x 10-5, Figure 3-8). A QQ-plot of the mRNA 
expression in hippocampal brain tissue samples is shown in Appendix, Figure 6-4. 
 
Figure 3-8: Manhattan plot for cis-eQTLs identified in 115 hippocampal brain tissue samples. 
The x-axis shows the genomic position of gene transcript start sites on chromosomes 1 to 22 (NCBI built 37.3, hg19); the y-
axis shows the negative log10 of the P-value per SNP/mRNA pair. The red line represents the threshold for significant cis-
eQTLs with FDR < 0.05. The genes of the 20 most significant cis-eQTLs (shown in Table 3-12) are highlighted. 
 
cis-eQTL confirmation analyses were performed by comparing my cis-eQTL analysis with three recent 
cis-eQTL studies investigating diverse postmortem brain tissues (Gibbs et al. 2010; Kim et al. 2014; 
Ramasamy et al. 2014). All studies used different assays to profile mRNA transcript in comparison to 
my analysis (for an overview on studies that are frequently mentioned for comparison reasons, 
please refer to Table 6-2 in Appendix). Therefore, the significant cis-eQTL SNPs from all three studies 
had to be within 1 Mbps of my mRNA transcription site and further their SNPs had to be in LD of r2 > 
0.2 with my cis-eQTL SNPs. In total, an overlap of 14% was observed in the significant cis-eQTLs 
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obtained from fresh frozen hippocampal brain tissue with those generated by Gibbs et al. (2010). 
Comparing the results of the present study to those found in the eQTL meta-analysis in brain cells 
(Kim et al. 2014) an overlap of 65% (474 out of 734) cis-eQTLs was observed. But the best overlap 
was detected by comparing results to those found in the eQTL analysis in ten regions of the human 
brain (Ramasamy et al. 2014): an overlap of 71% (522 out of 734) cis-eQTLs was observable, 
considering that a cis-eQTL signal was identified in more than one brain region. Considering only the 
hippocampal brain region, an overlap of 27% (197 out of 734) cis-eQTLs was identified (Table 3-11). 
In addition, Schramm and co-workers (2014) performed a whole-genome eQTL analysis in blood cell 
samples using the HT12v3 expression array, and the meta-eQTL analysis in blood cells carried out by 
Westra and colleagues (2013) was restricted to probes present on the HT12v3 array. I found that 50% 
of cis-eQTLs in hippocampal brain tissue matched to the cis-eQTLs in blood cells detected by 
Schramm et al. (2014), and 58% matched with those reported by Westra et al. (2013). 
Table 3-11: Cis-eQTL overlaps with comparable human eQTL studies. 
Epigenetic study Cell-type or tissue studied Overlap with cis-eQTL (FDR < 0.05)  
Gibbs et al. (2010) Postmortem brain tissue 14% (105 out of 734) 
Kim et al. (2014) Postmortem brain tissue 65% (474 out of 734) 
Ramasamy et al. (2014) Postmortem brain tissue 71% (522 out of 734) 
Schramm et al. (2014) Whole Blood 50% (367 out of 734) 
Westra et al. (2013) Whole Blood 58% (423 out of 734) 
 
The 20 most significant cis-eQTLs for 115 hippocampal brain tissue are shown in Table 3-12, including 
columns confirming the cis-eQTL results of the present study in diverse postmortem brain tissues 
(Gibbs et al. 2010; Kim et al. 2014; Ramasamy et al. 2014) as well as in blood cells (Westra et al. 2013; 
Schramm et al. 2014). 
 
  
 
Table 3-12: Top hits of cis-eQTLs in hippocampal brain tissue.  
mRNA probe mRNA 
Location 
Gene 
Symbol 
eQTL SNP SNP Pos FDR Detec P-
value > 0.05 
P-value 
(Brain
1
) 
P-value 
(Brain
2
) 
P-value 
(Brain
3
) 
P-value 
(Blood
4
) 
P-value 
(Blood
5
) 
ILMN_1719064 12:109886649 KCTD10 rs4766601 109890080 3.32E-35 115 5.02E-47 7.61E-09 1.25E-23 1.91E-230 9.81E-198 
ILMN_2209027 12:56436251 RPS26 rs10876864 56401085 1.17E-32 115 NA 6.99E-06 1.43E-15 NA NA 
ILMN_1753164 12:30782283 IPO8 rs10771758 30856139 1.66E-30 111 NA 6.53E-08 9.14E-19 < 1E-270 9.81E-198 
ILMN_1760708 22:25625496 CRYBB2 rs113130491 25861797 4.83E-30 110 NA NA NA NA NA 
ILMN_1809212 16:72110608 HPR rs2000999 72108093 1.68E-27 112 3.64E-10 1.06E-26 NA NA NA 
ILMN_1651745 11:118406322 TMEM25 rs56403966 118425051 3.37E-27 81 NA 5.42E-08 NA NA 1.12E-04 
ILMN_1765332 11:57296041 TIMM10 rs2649652 57324428 5.52E-27 115 2.89E-22 1.58E-14 8.78E-32 2.25E-198 9.81E-198 
ILMN_2389590 17:66528779 PRKAR1A rs2952272 66524565 1.05E-26 109 NA 1.68E-07 NA 1.42E-190 9.81E-198 
ILMN_2216918 17:3511949 SHPK rs62069929 3515275 2.78E-25 115 NA 1.11E-14 4.81E-14 1.66E-36 NA 
ILMN_1830462 16:17196448 XYLT1 rs9934313 17198524 1.14E-24 84 NA NA NA 1.98E-174 NA 
ILMN_2229649 13:77454497 KCTD12 rs73544577 77434063 4.02E-24 20 NA 2.87E-08 NA NA 3.76E-78 
ILMN_1710752 8:144656991 NAPRT1 rs9657360 144676862 2.20E-23 114 3.27E-18 2.18E-30 6.23E-32 3.24E-163 9.81E-198 
ILMN_2183938 12:65641975 LEMD3 rs193244911 65622186 2.20E-23 115 NA NA NA 6.88E-239 9.81E-198 
ILMN_2262288 11:62334905 EEF1G chr11:62369880:I 62369880 4.25E-23 115 NA 2.30E-23 NA 1.91E-254 NA 
ILMN_1798177 14:65401520 CHURC1 rs4902345 65403904 8.00E-23 115 5.77E-41 1.92E-29 3.79E-37 < 1E-270 9.81E-198 
ILMN_1851020 9:32454228 DDX58(1.0k) rs1360171 32454348 5.43E-22 44 NA NA NA NA NA 
ILMN_1664641 13:48650456 MED4 rs4942723 48525457 7.31E-22 115 NA 3.69E-07 4.49E-09 1.73E-239 9.81E-198 
ILMN_1704056 14:20811256 RPPH1 rs79030532 20814865 1.99E-21 83 NA 7.02E-08 NA NA NA 
ILMN_1774949 21:38445331 PIGP rs1793870 38481436 6.26E-20 104 NA 3.78E-12 1.75E-24 3.42E-75 NA 
ILMN_1745116 20:25275591 ABHD12 rs6107052 25530838 8.38E-20 115 NA 7.52E-39 7.11E-10 6.61E-46 9.81E-198 
Abbreviations: mRNA probe, Illumina annotation of the mRNA probe; mRNA Location, chromosome of the mRNA probe and the average of the start and end position of the mRNA probe; Gene 
Symbol, gene which contains the mRNA probe; eQTL SNP, SNP of most significant eQTL of a specific mRNA probe; SNP Pos, base-pair position of SNP; FDR, most significant FDR for a SNP/mRNA 
pair; Detec P-value > 0.05, number of samples with detection P-value > 0.05; P-value Brain1, cis-eQTL P-value according to Gibbs et al. (2010); P-value Brain2, P-value according to Ramasamy et al. 
(2014); P-value Brain3, cis-eQTL P-value according to Kim et al. (2014), meta-analysis; P-value Blood4, cis-eQTL P-value according to Schramm et al. (2014); P-value Blood5, cis-eQTL P-value 
according to Westra et al. (2013), meta-analysis. All annotations refer to genome build hg19. 
4
7
 
 R
ESU
LTS 
RESULTS 
48 
 
3.2.1.1 Enrichment analysis of cis-eQTLs 
Enrichment analyses for the cis-eQTLs were performed using the same gene-sets as for the cis-
meQTL enrichment analysis; brain expressed genes (N = 8,852; Pinto et al. 2014), genes involved in 
neurodevelopmental disorders (N = 1,689) and autism spectrum disorder (N = 1,559), as well as the 
previously described Brain-Disorder-GWAS gene-set (N = 1,200). The analysis revealed no 
significantly enrichment in the gene-sets. Here, the significant enrichment in brain expressed genes 
(P = 1.35 x 10-12) could be seen as a kind of validation for performing the enrichment analysis in these 
cis-eQTLs. 
3.2.2 Trans-eQTL analysis in hippocampal brain tissue 
After stringent quality control, 31,146 mRNA probes and 643,195 LD-pruned SNPs were correlated 
for trans-eQTL analysis, resulting in 1.68 x 1010 tests corresponding to a nominal significance 
threshold of 3.79 x 10-11 at a FDR of 5%. At the FDR threshold of 5%, 16 significant trans-acting eQTLs 
were observed (P-value range = 3.06 x 10-35 to 3.79 x 10-11). Overall, 15 of the trans-eQTLs had SNPs 
from different chromosomes than the respective mRNA probe while one was on the same 
chromosome but more than 70 Mbps away from the target mRNA probe. Thus, there was no 
evidence for long-range cis-eQTLs.  
With regard to the rare trans-eQTL findings, only four trans-eQTL SNPs were significantly associated 
with expression levels of two genes (Table 3-13). None of the obtained trans-eQTL genes overlap 
with those reported in previously published eQTL studies (Gibbs et al. 2010; Westra et al. 2013; 
Ramasamy et al. 2014; Schramm et al. 2014). 
Table 3-13: Master regulatory sites – trans-eQTL SNPs with simultaneous impact on the expression of two genes. 
SNP Chr 
SNP 
Gene of SNP SNP Pos mRNA Gene of 
mRNA 
mRNA Location FDR 
rs10876864 12 IKZF4(0.4k) 56401085 ILMN_1678522 LOC644934 15:64885219 6.12E-25 
 12 IKZF4(0.4k) 56401085 ILMN_2310703 RPS26L 13:101192220 3.30E-24 
rs17718169 5 ATP6V0E1(4.9k) 172405897 ILMN_1666845 KRT17 17:39775733 3.89E-06 
 5 ATP6V0E1(4.9k) 172405897 ILMN_1689515 CPLX3 15:75123999 5.41E-03 
rs2069408 12 DGKA(16.5k) 56364321 ILMN_2310703 RPS26L 13:101192220 8.81E-05 
 12 DGKA(16.5k) 56364321 ILMN_1678522 LOC644934 15:64885219 1.92E-02 
rs12340642 9 NA 79893032 ILMN_1713668 TSNAX 1:231700328 1.09E-02 
 9 NA 79893032 ILMN_1718712 C20orf177 20:58522158 4.13E-02 
Abbreviations see Table3-12. 
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3.3 Delineation of methylation-driven gene expression in hippocampal brain 
tissue  
3.3.1 Correlation analysis of CpG methylation with gene expression 
By correlating local CpG methylation with mRNA gene expression, 565 CpG-expression probe pairs 
(comprising 565 CpG sites and 292 expression probes of 378 genes) displayed a significant correlation 
(P-value range = 7.58 x 10-30 to 2.38 x 10-6), of which 152 were positively correlated (Pearson 
correlation coefficient r = +0.42 to +0.80) and 413 showed an inverse correlation (r ranged from -0.83 
to -0.42). 
Overall, 27% (152 of 565) of the significant CpG-mRNA pairs were correlated in the same direction 
(positive correlation). Namely, a pattern whereby high methylation levels were associated with high 
expression levels was observed. This pattern was observed both for methylation sites located within 
and outside gene bodies. Yet, CpG sites whose methylation levels were positively correlated with 
expression levels of nearby genes were more distant from the gene’s TSS than CpG sites whose 
methylation levels were inversely correlated with expression levels of nearby genes (median distance 
of 8,954 bps and 5,766 bps for positive correlation and inverse correlation, respectively; P = 0.038). 
In total, 73% (413 of 565 sites) of the significant cis CpG-expression probe pairs were observed with 
an inverse correlation, demonstrating that high methylation states result in low mRNA expression 
levels. When considering only those CpG-mRNA probe pairs where the CpG site was within a CpG 
island (as defined in Gardiner-Garden & Frommer 1987) 96 CpG sites were identified. Of those 96 
CpG sites, 71% (68 out of 96) of the CpG-mRNA probe pairs were inversely correlated. 
The correlation analysis of CpG methylation to gene expression demonstrated that the CpG sites 
affecting mRNA expression were enriched in gene bodies (P = 1.85 x 10-3) and at strong enhancers 
(P = 3.41 x 10-38). A depletion of CpG-mRNA probe pairs compared to all 362k CpG sites was observed 
in the TSS200 region (P = 0.04). Interestingly, further differences between positive and inverse 
correlation of the CpG-expression probe pairs were observed. As mentioned, I was able to identify 
enrichment in gene bodies but did not observe a difference in the direction of correlations between 
CpGs within or outside gene bodies. When comparing all 362k CpGs sites with the distribution of 565 
correlated CpG-mRNA probe pairs at active promoters, no significant difference was observed. But 
when comparing positive with inverse correlation at active promoters a significant difference was 
observable (P = 9.43 x 10-3): CpG-expression probe pairs showing inverse correlation displayed 
enrichment at active promoters, CpG-expression probe pairs showing positive correlation displayed 
depletion at active promoters. In addition, the same distribution was observed for the TSS200 region 
where a moderate difference between the correlation types was detected (P = 0.01) and at strong 
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enhancers which revealed the strongest difference between the correlation types (P = 1.58 x 10-4; 
Table 3-14). 
Table 3-14: Genomic distribution of CpGs influencing gene expression in gene features in hippocampal brain tissue. 
First table: proportion of all quality-filtered 362,722 CpGs in gene features. Pearson's Chi-squared test with Yates' continuity 
correction was used to calculate the distribution of 565 CpG-mRNA probe pairs (FDR < 0.05) in different gene features in 
hippocampal brain tissue compared to all 362k CpG sites. Red colored background indicates depletion, green colored 
background an enrichment of CpG-mRNA probe pairs compared to all 362k CpGs. The second table shows the genomic 
distribution of positive or inverse correlated CpG-mRNA probe pairs. Differences of the correlation types are highlighted. 
Illumina Group All, 362,722 CpGs Correlation CpG-mRNA P-values, correlation 
3'UTR 3.72% 3.19%        5.74E-01 
5'UTR 9.15% 11.33%        8.50E-02 
Gene Body 34.06% 40.35%*      1.85E-03 
TSS200 10.98% 8.14%*      3.70E-02 
TSS201-1500 14.62% 17.35%        7.50E-02 
Active Promoter
1
 19.89% 20.35%        8.25E-01 
Strong Enhancer
1
 4.06% 14.87%*** 3.41E-38 
Insulator
1
 1.62% 1.24%        5.76E-01 
1
These genomic features are from cell line GM12878. 
Chi-square test: ***P < 10
-30
; **P < 10
-5
; * P < 0.05 
 
Illumina Group Correlation 
CpG-mRNA 
Inverse correlation Positive correlation P-values, correlation 
3'UTR 3.19% 2.66%   4.61%   2.80E-01 
5'UTR 11.33% 11.14%   11.84%   8.81E-01 
Gene Body 40.35% 39.47%   42.76%   4.99E-01 
TSS200 8.14% 9.20%* 5.26%* 1.00E-02 
TSS201-1500 17.35% 16.46%   19.74%   3.81E-01 
Active Promoter
1
 20.35% 23.00%* 13.16%* 9.43E-03 
Strong Enhancer
1
 14.87% 18.16%* 5.92%* 1.58E-04 
Insulator
1
 1.24% 0.73%   2.63%   8.80E-02 
1
These genomic features are from cell line GM12878. 
Chi-square test: ***P < 10
-30
; **P < 10
-5
; * P < 0.05 
 
To further explore the correlation of CpG methylation with mRNA gene expression the allelic status 
of these was tested. The significant CpG-mRNA probe pairs were selected where both the CpG 
methylation site and the mRNA transcript probe had a positional overlapping cis-meQTL or cis-eQTL 
finding. Overall, 102 of 565 CpG-expression probe pairs (comprising 102 CpG sites and 45 expression 
probes) had a positional overlapping cis-meQTL and cis-eQTL finding. For only one of the 102 
correlations of CpG methylation with mRNA gene expression, neither the same meQTL-eQTL SNP nor 
a meQTL SNP in LD (r2 ≥ 0.2) with an eQTL SNP was found. In total, for 18% of the CpG methylation-
expression correlation the CpG methylation and – presumably indirect – the RNA expression was 
significant genetically determined.  
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The 10 most significant correlations of CpG methylation with mRNA gene expression and their 
associated significant cis-meQTLs and cis-eQTLs are shown in Table 3-15. In total, 44 genes showed 
SNP-methylation-expression three-way associations; the same SNP (or two times an LD SNP) 
simultaneously showed significant association with both DNA methylation and gene expression, 
while DNA methylation was significantly correlated with gene expression. The 44 genes involved 101 
CpG sites, 44 expression probes, and 340 SNPs. 
  
 
Table 3-15: Top hits of CpG methylation-driven gene expression in hippocampal brain tissue. 
Probe CpG Chr Gene Symbol R FDR CpG Pos mRNA Location Correlated SNP SNP Pos FDR, cis-meQTL FDR, cis-eQTL 
ILMN_1710752 cg17524265 8 NAPRT1 -0.83 1.06E-22 144659883 8:144656991 rs9657360 144676862 3.20E-33 2.20E-23 
ILMN_1730054 cg11141652 22 GSTT1 0.80 4.44E-20 24348549 22:24376401 rs738809 24405492 1.42E-06 1.88E-11 
ILMN_2326324 cg07415359 11 LDHC -0.80 8.07E-20 18434354 11:18472557 rs4757651 18417583 2.20E-27 1.55E-16 
ILMN_1736184 cg10807101 1 GSTM5 -0.69 1.76E-11 110282274 1:110276633 rs1887547 110295772 2.91E-15 8.75E-09 
ILMN_2173294 cg04051697 2 THNSL2 -0.66 8.56E-10 88470813 2:88486079 rs7582011 88452740 1.67E-06 4.64E-14 
ILMN_1746646 cg24786847 15 CHRM5 -0.64 6.87E-09 34261172 15:34357171 rs618868 34293378 1.35E-06 1.05E-05 
ILMN_1899338 cg19520046 6 KIF25 -0.63 2.26E-08 168397360 6:168376777 rs11752225 168409629 1.53E-04 7.32E-07 
ILMN_1732089 cg25755428 19 MRI1(0.1k) -0.62 5.50E-08 13875111 19:13884988 rs371671 13870153 5.32E-27 5.53E-09 
ILMN_1774949 cg21832243 21 PIGP 0.61 3.21E-07 38444223 21:38445331 rs1793870 38481436 3.61E-14 6.26E-20 
ILMN_1809212 cg23815491 16 HPR 0.59 1.14E-06 72088622 16:72110608 rs2000999 72108093 1.10E-10 1.68E-27 
Abbreviations: R, Pearson correlation coefficient; Genes in the ‘Gene Symbol’ column indicate the gene of the mRNA probe. All annotations refer to genome build hg19. 
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One of these genes encodes the Nicotinate Phosphoribosyltransferase (NAPRT1). A cis-eQTL 
regulating NAPRT1 expression has been reported in several meta-eQTL analyses in brain cells (Gibbs 
et al. 2010; Kim et al. 2014), in whole blood cells (Westra et al. 2013; Battle et al. 2014) as well as in 
CD14+ monocytes (Raj et al. 2014; Gjoneska et al. 2015). The inverse correlation (r-value range = -
0.83 to -0.72) of seven successive CpG probes in the promoter region of NAPRT1 with the NAPRT1 3’ 
expression probe ILMN_1710752 was the strongest methylation-driven expression in the present 
study (P-value range = 7.58 x 10-30 to 7.0 x 10-20). The seven CpG probes (cg17524265, cg08017634, 
cg16316162, cg13282195, cg19357499, cg01494348, cg21187068; chr8:144,659,627-144,660,772) 
flank the TSS of NAPRT1. Five of these CpGs reside in a CpG island (chr8:144,659,745-144,660,635; 
assigned as CpG: 94). Two additional CpGs are located in the 2 kb region flanking CpG island shores. 
Moreover, the NAPRT1-associated meQTLs and eQTL were genetically regulated by the same SNP 
rs9657360 (Pmin = 1.61 x 10
-39 and P = 2.15 x 10-29, respectively). The minor C allele of SNP rs9657360 
was significantly associated with high methylation levels in the NAPRT1 promoter region and 
simultaneously associated with low gene expression of NAPRT1. The box plot of methylation 
(cg17524265) and expression (ILMN_1710752) in the NAPRT1 gene with SNP rs9657360 is shown in 
Figure 3-9 as well as the significant inverse correlation between methylation and expression. The 
methylation and expression levels are represented by their residuals. 
 
Figure 3-9: DNA methylation and gene expression of NAPRT1 plotted by genotypes of rs9657360. 
DNA methylation (left) and gene expression (middle) of NAPRT1 is correlated with genotypes of SNP rs9657360. The x axis 
harbors three genotypes of rs9657360, and the y axis displays residuals representing DNA methylation and gene expression 
levels. Minor allele C is significantly associated with high methylation level of NAPRT1 in a cis-manner and simultaneously 
associated with low gene expression of NAPRT1. The scatter plot (right) indicates the linear inverse correlation between 
methylation and expression and differentiates the three genotype clusters of the CpG methylation and mRNA expression 
profiles. Blue dots, genotype CC; black dots, genotype CT, and red dots, genotype TT. 
 
The SWAN corrected and quantile normalized ß -values representing methylation levels of 
cg17524265 show the following values for the genotypes of SNP rs9657360: CC, ß-value of 0.71; CT, 
ß-value of 0.54 and TT, ß-value of 0.40. Equally, the quantile normalized log2-values representing 
expression levels of ILMN_1710752 show the following values for the genotypes of SNP rs9657360: 
CC, log2-ratio of 6.95; CT, log2-ratio of 7.64 and TT, log2-ratio of 8.03. 
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The NAPRT1 region including CpG cg17524265 (plus additional six CpG probes), expression probe 
ILMN_1710752 and SNP rs9657360 is illustrated in Figure 3-10. 
 
           
Figure 3-10: NAPRT1 region. 
The SNP-methylation-expression three-way association of the NAPRT1 region is illustrated. CpG cg17524265, mRNA probe 
ILMN_1710752 and SNP rs9657360 are highlighted in red. The additional six CpGs which are associated with the mRNA 
probe are marked in blue (blue lines). It is shown that the CpG probes reside in a CpG island (CpG: 94) encompassing the TSS 
and the promoter region of NAPRT1. 
 
3.4 Exploration of the role of QTL-associated rSNPs in common neuropsychiatric 
disorders 
The results of the enrichment analyses demonstrated that meQTLs in hippocampal brain tissue were 
positional overrepresented in the Brain-Disorder-GWAS gene-set (P = 5.79 x 10-4). Therefore, it was 
examined, whether rSNPs affecting transcription factor binding sites underlie both the cis-acting 
QTLs (meQTLs and eQTLs) and the regional GWAS hits, to pinpoint causative rSNPs. 
3.4.1 Co-occurrence of cis-acting meQTLs and GWAS hits 
The analysis was restricted to GWAS signals with P < 5 x 10-8, meQTLs with FDR < 0.05 and LD of the 
GWAS lead SNP and meQTL SNP with r2 ≥ 0.5. Overall, 52 GWAS lead SNPs (P < 5 x 10-8) were in 
strong LD (r2 ≥ 0.5) with one of the identified cis-meQTL SNPs. Strong LD of the GWAS lead SNPs and 
cis-meQTL SNPs is shown for six cis-meQTLs in hippocampal brain tissue in Table 3-16. 
  
 
Table 3-16: GWAS lead SNPs in strong LD with cis-acting meQTLs in hippocampal brain tissue.  
CpG Chr CpG Pos meQTL SNP SNP Pos FDR LD SNP  
GWAS-meQTL 
GWAS 
SNP 
GWAS 
P-value 
Disease Gene Symbol PMID 
cg02586212 1 192544902 rs1359062 192541472 2.21E-17 0.99 rs1323292 2.0E-08 MS RGS1 21833088 
cg22674798 1 3096360 rs207200 3073555 6.17E-07 0.80 rs2651899 4.0E-14 Migraine PRDM16 23793025 
cg18099408 3 52552593 rs6445529 52662722 1.38E-14 0.96 rs2251219 2.0E-09 BD,MDD PBRM1 20081856 
cg18404041 3 52824283 rs2710331 52837855 3.25E-14 0.88 rs2535629 3.0E-12 AUT,ADHD,BD,MDD,SCZ ITIH3 23453885 
cg22298860 6 29690822 rs1362125 29691090 3.26E-21 0.75 rs2523393 1.0E-17 MS HLA-F 19525953 
cg13165778 7 1952518 rs6950151 1953521 3.52E-23 0.74 rs6461049 6.0E-13 SCZ MAD1L1 23974872 
Abbreviations: ADHD, attention-deficit hyperactivity disorder; AUT, autism; BD, bipolar disorder; MDD, major depressive disorder; MS, multiple sclerosis; SCZ, schizophrenia. GWAS associations 
exceeding P-values < 5 x 10
-8
 from the NHGRI GWAS catalog, LD of GWAS SNPs and meQTL SNPs with r
2
 ≥ 0.5 and an FDR of 5% for meQTLs. 
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3.4.2 Co-occurrence of cis-acting eQTLs and GWAS hits 
My exploration was focused on GWAS hits with P < 5 x 10-8, eQTLs with FDR < 0.05 and LD of GWAS 
SNP and eQTL SNP pairs with r2 ≥ 0.5. Two SNPs of eQTLs were in strong LD with two GWAS lead 
SNPs, respectively. These findings included the following traits: schizophrenia (AS3MT; GWAS P-value 
= 4 x 10-14; Ripke et al. 2013) and multiple sclerosis (CLECL1; GWAS P-value= 3 x 10-10; International 
Multiple Sclerosis Genetics Consortium 2010). 
 
  
DISCUSSION 
57 
 
4. DISCUSSION 
One of the main goals of human genetics is to elucidate molecular mechanisms underlying disease 
susceptibility. Up until today, neuropsychiatric disorders are among the most complex and poorly 
understood conditions. Genome-wide association studies (GWASs) have captured more than two 
thousand susceptibility loci increasing risk of brain disorders (Kim et al. 2014). However, the majority 
of these susceptibility loci reside in non-coding regions and their functional consequences remain 
elusive. Therefore, the question arises whether regulatory sequence variants affecting DNA 
methylation and gene expression may be the causal susceptibility alleles (Maurano et al. 2012). 
The present study aimed to identify regulatory SNPs (rSNPs) that quantitatively influence CpG 
methylation (meQTL) and mRNA expression (eQTL) and aimed to dissect those rSNPs that confer 
susceptibility to common brain disorders. To achieve this aim, large-scale data sets of SNPs, CpG 
methylation states and gene expression profiles of 115 individual samples of fresh frozen 
hippocampal brain tissue obtained by epilepsy surgery have been integrated using a novel and 
promising approach. A particular strength of the present study arises from the application of the 
Human Methylation450k (HM450) array and the superior quality of fresh frozen brain tissue from a 
uniform region of the hippocampus (Grote et al. 2015). These advantages resulted in a six-fold 
increase of identified meQTLs compared to previous studies with postmortem brain tissue using the 
Human Methylation27k (HM27) array (Gibbs et al. 2010; Zhang et al. 2010; Numata et al. 2012; 
Gamazon et al. 2013; Numata et al. 2014; Smith et al. 2014). The present study is the first that 
systematically examined the influence of cis-meQTLs on gene expression in fresh frozen brain tissue 
to delineate methylation-driven genes. Based on the advances of the 1000 Genomes Project (1000 
Genomes Project Consortium 2010), I was also able to improve the quality check (QC) filtering 
procedures for the CpG methylation (Barrow and Byun 2014) and mRNA expression probes (Westra 
et al. 2013). In detail, I was successful in removing artificial findings more accurately and refined the 
quantitative assessment of methylation and expression profiles by implementing a correction for 
cell-type heterogeneity in the QTL regression analyses (Guintivano et al. 2013). Although recent 
studies start to consider cellular heterogeneity among different brain regions (De Jager et al. 2014; 
Pidsley et al. 2014; Xiao et al. 2014), there are yet no comparable studies which focus on 
neuropsychiatric disorders and perform simultaneously large QTL analyses. 
Another major achievement of this study will be the public release of a database reporting the 
complete meQTL and eQTL findings in context of the publication of this study. These genome-wide 
maps of meQTLs and eQTLs will improve the prospects to elucidate the genetic mechanisms 
determining DNA methylation and gene expression, to explore the interplay of DNA methylation and 
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gene expression, and to extend the allelic spectrum of disease genes of common disorders with 
complex genetic predisposition. Using the same array platform and analytical procedures, a genome-
wide map of cis- and trans-meQTLs in whole blood cells of 496 German population controls without 
neuropsychiatric disorders was generated as well. With regard to the strong overlap of meQTLs in 
brain and blood cells, this thesis provides the prerequisites to establish easily accessible epigenetic 
biomarkers in blood cells for disease-associated cis-meQTLs in brain. 
 
4.1 Autosomal map of cis-meQTLs in human hippocampal brain tissue 
This study represents the largest meQTL study in human brain tissue reported so far. To the best of 
my knowledge, this study is the first study which uses the HM450 array on specimens of fresh frozen 
human brain tissue. After careful and highly conservative quality filtering procedures, 362,722 
autosomal CpGs were included in the meQTL analysis. Previous meQTL studies have been used the 
smaller HM27 array (27,578 CpGs) and investigations were based on postmortem brain tissue (Gibbs 
et al. 2010; Zhang et al. 2010; Numata et al. 2014; Smith et al. 2014; for an overview on studies that 
are frequently mentioned for comparison reasons, please refer to Table 6-2 in Appendix), what might 
entail unwanted side effects (e.g. alterations in DNA methylation profiles from baseline; cf. 1.5 
Quantitative trait loci). Four previous publications of meQTL studies using the HM27 array in brain 
tissue revealed at the maximum about three thousand (range per study: 887 - 3,612) cis-meQTLs per 
study (Gibbs et al. 2010; Zhang et al. 2010; Numata et al. 2014; Smith et al. 2014). However, with the 
present layout I was able to identified 19,954 (out of 362k CpG sites, see above) at which 
methylation levels are significantly influenced by nearby genetic variations, demonstrating that cis-
acting meQTLs are abundant in the autosomal genome. The vast majority (76%) of cis-acting meQTL 
SNPs displaying the strongest impact on CpG methylation were located within a genomic region of 
150 kb around the CpG site. In total, 67% of the identified cis-meQTLs are located intragenic or 
nearby 7,827 Ensembl genes (± 50 kb). Notably, a strong enrichment of cis-meQTLs upstream 
(TSS201-TSS1500) of the gene promoter region (Table 3-1) was found, highlighting the functional 
impact of this 5´-regulatory region in the epigenetic regulation of gene expression. 
The before mentioned four previous studies have reported 5,061 cis-meQTLs in postmortem brain 
tissue altogether, of which 3,566 quality-filtered CpG sites were also assessed in my study and 2,353 
cis-meQTLs were also identified as significant cis-meQTL. This strong overlap of the cis-meQTLs 
identified in previous studies of brain tissue support the validity of the overlapping cis-meQTLs 
observed in the present study. 
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The enrichment analyses of genes associated with cis-meQTLs indicated an overrepresentation of 
genes implicated in neurodevelopmental disorders (Krumm et al. 2013) and GWAS hits of brain 
disorders (Welter et al. 2014). Some of the most significant cis-meQTLs identified within my work are 
located in genomic regions of several high-ranking candidate genes for neurodevelopmental 
disorders, such as ADARB2, HDAC4, NAPRT1, MAD1L1, PTPRN2, and RIMBP2 (cf. Table 3-5). 
The present cis-meQTL and eQTL findings strongly suggest that sequence variants affecting 
regulatory elements of gene expression or mRNA splicing contribute to the allelic spectrum of 
disease mutations besides the traditional deleterious exonic and splice-site variants detected by 
next-generation sequencing (NGS) based whole exome sequencing approaches. At the gene level, 
these cis-meQTL and -eQTL findings will guide the identification of the causative regulatory sequence 
variants. 
Notably, the SNP showing the strongest correlation with the individual CpG methylation states is not 
necessarily the regulatory SNP causing the modulating effect. The identified meQTL SNP could be in 
strong linkage disequilibrium (LD) with the ‘real’ rSNP which may not be included in the SNP 
screening set. Consequently, all known SNPs in strong LD with the identified meQTL SNP would have 
to be examined for their functional alteration of regulatory elements, such as binding sites for 
transcription factors (TFs), microRNAs, DNaseI hypersensitive sites and regions of histone 
modifications (Li et al. 2013). Advances of the systematic exploration of regulatory elements of the 
human genome (Kundaje et al. 2015) have accelerated progress in the dissection of rSNPs. However, 
deeper insights into the regulatory mechanisms are still required to differentiate the role of potential 
rSNPs in context of spatial and temporal aspects of gene expression (Januar et al. 2015). 
4.1.1 Gene-centric distribution of cis-meQTLs 
To explore the gene-centric distribution of the 19k cis-meQTLs identified in hippocampal brain tissue, 
the localization of the CpGs of the identified cis-meQTLs with the distribution of all QC-filtered 362k 
CpG sites was compared. A relative positional depletion of cis-meQTLs in the promoter region of 
genes (TSS200 region) was observed, whereas a relative enrichment was found in intergenic regions 
and in the 5´-regulatory region of genes upstream of the promoter region (TSS201-TSS1500). The 
TSS201-1500 region includes well known regulatory elements, such as the insulator CTCF, which is 
known to exhibit a variable binding affinity of CTCF due to differential CpG methylation at its binding 
site (Wendt et al. 2008). Specifically, 8.45% (N = 3,055) cis-meQTLs were detected in the TSS201-
TSS1500 region compared to 3.6% of all 362k CpG sites (P = 7.7 x 10-61). These findings indicate that 
methylation-driven gene regulation occurs more likely in regions upstream of the gene promoter, a 
region which harbors important regulatory elements, such as enhancers and insulators (Jones 2012). 
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The observed depletion of meQTLs at active promoters is in line with findings of previous studies 
(Gibbs et al. 2010; Gutierrez-Arcelus et al. 2013; Banovich et al. 2014; De Jager et al. 2014; Kundaje et 
al. 2015), demonstrating that DNA methylation levels at promoters seem to be less variable and have 
a lower average methylation level compared with other genomic regions, especially enhancers. 
It should also be mentioned that a similar gene-centric distribution of cis-meQTLs in hippocampal 
brain tissue and blood cells was observed, suggesting that a large proportion of meQTLs share similar 
methylation control mechanisms in both tissues. 
4.1.2 Enrichment analysis of cis-meQTLs 
It was evaluated whether the found significant cis-meQTLs were enriched in four gene-sets 
comprising genes implicated in neurodevelopmental disorders and common traits of the central 
nervous system. Enrichment analysis showed that cis-meQTLs of the hippocampal brain tissue were 
significantly enriched in susceptibility genes of GWAS hits of brain disorders (P = 5.8 x 10-4) published 
in the NHGRI GWAS catalog (Welter et al. 2014) and in genes previously implicated in 
neurodevelopment disorders (P = 0.04, Krumm et al. 2013). As diverse functional gene-set 
categories, e.g. GO categories, are biased according to gene size and the variable coverage of 
meQTLs (Geeleher et al. 2013; Lockett et al. 2013; Adams et al. 2014; Berko et al. 2014; Delahaye et 
al. 2014), enrichment results were corrected for the numbers of CpG sites located in different classes 
of genes. 
The enrichment of susceptibility genes implicated by GWAS hits of brain disorders and 
neurodevelopmental disorders emphasizes, that regulatory SNPs and their effects on CpG 
methylation and gene expression may confer a substantial contribution to the genetic basis of 
common neuropsychiatric disorders. 
4.1.3 Tissue-specifity of cis-meQTLs in hippocampal brain cells 
To explore tissue-specifity of the cis-meQTLs detected in hippocampal brain tissue, the same array 
platform and analytical procedures were also applied in an additional meQTL analysis of whole blood 
cells originated from 496 German population controls without neuropsychiatric disorders. The main 
reasoning behind this analysis is the mere instance that whole blood cells are much more easily 
accessible as compared to fresh frozen or postmortem brain tissue. In fact, whole blood cells are the 
most convenient source of tissue for the establishment of epigenetic biomarkers. 
Within the analysis more than 108k cis-meQTLs were identified in whole blood cells at a FDR < 0.05. 
Comparison of cis-meQTLs detected in hippocampal brain tissue with those found in blood cells 
showed an 65% overlap with a substantial correlation (Spearman’s Rank coefficient = 0.42). However, 
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65% overlap entail that 35% of the CpG sites of cis-meQTLs in brain tissue had no cis-meQTL 
counterpart in the blood cells. Furthermore, these discordant brain-specific cis-meQTLs includes 
genes involved in epileptogenesis, such as GABRB3 (Epi4K Consortium & Epilepsy Phenome/Genome 
Project 2013), GRIN2A (Lemke et al. 2013), CHRNB2 (Steinlein 2000) and RBFOX1 (Lal et al. 2013). 
Hence, this finding demonstrates that brain-specific meQTL analyses are inevitable to identify all 
rSNPs contributing to common brain disorder. However, results suggest that meQTLs found in whole 
blood cells are frequently representative for meQTLs in brain tissue and may be suitable as 
epigenetic biomarkers for brain disorders. The present database of cis-meQTLs in brain and blood 
cells allows differentiating those cis-meQTLs that are present in both tissues or those that only occur 
in brain-tissue but not in whole blood cells. Epigenetic biomarkers could lead to improvements in 
diagnosis and options for early intervention therapies (Januar et al. 2015). 
 
4.2 Autosomal map of trans-meQTLs in human hippocampal brain tissue 
Altogether, 2,436 CpG sites at which methylation levels in hippocampal brain tissue are significantly 
associated with genetic variations in trans (3,927 trans-meQTLs) were identified. For trans-meQTL 
analysis it was tried to minimize ambiguous trans-signals due to cross-hybridization of CpG probes at 
additional genomic localizations. Therefore, the HM450 set of CpGs was reduced to 268,397 CpGs, 
according to more robust and conservative quality-filters applied by Zhang and colleagues (2014) 
which included a careful genome-wide screen for cross-hybridization of the HM450 CpG probes. 
Furthermore, the potential effect that SNPs on the regulation of genes in trans resulted from long-
range cis-relationships was checked and excluded. These additional filters reduced the number of 
potentially trans-regulated CpG sites from 3,579 to 2,436 CpGs (and 8,989 to 3,927 for trans-
meQTLs). This small sample size used for generating trans-meQTLs largely limited the power to 
detect trans signals that had previously been implicated in methylation, rendering these analyses 
even more difficult to interpret. These results demonstrate the complexity of handling trans-acting 
QTL results and the possibility of a large number of potentially spurious trans-meQTL findings. 
 
4.3 Genome-wide assessment of imprinting meQTLs in GGE parent-offspring 
trios 
The objective of the imprinting meQTL (imeQTL) analysis was the dissection of CpG sites which are 
differentially methylated depending on their parental origin. Imprinted genes are of particular 
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interest because they are prone for susceptibility effects due to their Parent-of-Origin (PofO) 
dependent monoallelic gene expression. 
My imeQTL analysis in 269 parent-offspring trios revealed 177 CpGs at 31 genomic loci exhibiting 
differential methylation in a parent-of-origin dependent manner, of which nine loci were already 
known (Fang et al. 2012; Wei et al. 2014) and 22 were novel imprinted loci. The detection of nine 
known imprinting loci can be considered as proof-of-principle of the applied screening approach 
which compared the CpG methylation states of individuals with parentally inverse heterozygous 
genotypes of nearby SNPs (Garg et al. 2012). A 1.8-fold increase of paternally imprinted genes 
compared to maternally imprinted genes was observed. Of the nine known imprinting regions eight 
imprinted genes are expressed by the paternal allele, and only one is expressed from the maternal 
allele. 
PofO effects are present when the phenotypic effect of an allele depended upon its paternal origin, 
hence, whether it was inherited from the mother or the father. Strong PofO methylation effects at 
loci encompassing neurodevelopmental genes, such as the Nucleosome Assembly Protein 1-Like 5 
retrogene (NAP1L5), Neuronatin (NNAT) and Nischarin (NISCH) were observed. NAP1L5 is a 
chromatin-modifying protein critical for neuronal development, which is most abundantly expressed 
in neural tissues (Smith et al. 2003). NNAT is a dendritically expressed Ca2+ regulator and may play a 
crucial role in synaptic and possibly cognitive function in the hippocampus (Oyang et al. 2011). NISCH 
is differentially expressed in rat brain, regulates neuronal migration (Ding et al. 2013) and has been 
implicated to play a role in brain development, dementia, brain cancers and neurodegenerative 
disorders (Ding et al. 2013; Ostrow et al. 2013). 
Those imeQTLs detected on chromosome 3p21.1 are of special interest, considering that GWAS 
findings of several neuropsychiatric diseases, such as major mood disorder (McMahon et al. 2010), 
schizophrenia and bipolar disorder (Cross-Disorder Group of the Psychiatric Genomics Consortium et 
al. 2013; Sleiman et al. 2013), as well as autism spectrum disorder and attention deficit-hyperactivity 
disorder (Cross-Disorder Group of the Psychiatric Genomics Consortium et al. 2013) have been 
mapped to this candidate region. 
A recently published study investigates the effects of genetic variation and parental origin on gene 
expression in mice (Crowley et al. 2015). Crowley and co-workers (2015) showed that cis-regulated 
genes in human blood often have a counterpart in the mouse orthologue. Comparison of my 
imeQTLs in blood cells with those eQTLs displaying imprinting effects in mice revealed a substantial 
overlap: 138 out of 177 imeQTL CpGs were located intragenic of 78 Ensembl genes, of which eight 
(10%) overlapped with imprinted genes detected in mouse brain by Crowley and co-workers (2015). 
DISCUSSION 
63 
 
Additionally, Crowley and co-workers (2015) observed a global allelic imbalance in expression 
favoring the paternal allele comparable to the allelic imbalance of CpG methylation detected in my 
imeQTL analysis. 
Overall, only few PofO specific allelic associations at imprinted loci have been described for complex 
traits so far (Lawson et al. 2013). Genes at genomic loci showing imprinting effects should be 
prioritized as promising candidate genes because of their potentially monoallelic gene expression 
which may unmask recessive susceptibility alleles. 
 
4.4 Autosomal map of cis-eQTLs in human hippocampal brain tissue 
To examine the influence of cis- and trans-acting genetic variations on mRNA expression in human 
brain tissue, the Human HT-12 v3 (HT12v3) array was used to measure the expression profiles of 
31,146 QC-filtered mRNA target sequences in 115 samples of fresh frozen hippocampal brain tissue. 
Altogether 734 mRNA probes were identified for which expression levels were significantly 
influenced by cis-acting SNPs. 
Up until now, only few eQTL studies of human brain tissue focus on common brain disorders while 
employing none candidate gene approaches. The few published studies using brain tissue suffer from 
small sample sizes and they do not replicate well (Kim et al. 2014). However, notable overlap was 
found comparing the 734 cis-eQTL results with those reported in previous eQTL studies (Gibbs et al. 
2010; Kim et al. 2014; Ramasamy et al. 2014). With respect to an eQTL meta-analysis in postmortem 
brain cells (Kim et al. 2014), a 65% overlap was found (474 out of 734). An even higher overlap of 
71% was found with an eQTL study based on human brain tissue from ten different regions using the 
Affymetrix Human Exon 1.0 ST array (Ramasamy et al. 2014), considering that a cis-eQTL signal was 
identified in more than one brain region. Altogether, these overlapping eQTL findings underline the 
validity of the cis-eQTLs identified in this study. 
Also, comparisons with previous eQTL meta-analysis in blood cells render interesting and notable 
overlap (Westra et al. 2013; Schramm et al. 2014). Schramm and co-workers (2014) performed a 
whole-genome eQTL analysis in 890 blood cell samples using the HT12v3 expression array, and the 
meta-eQTL analysis in 5,311 blood cells carried out by Westra and colleagues (2013) was restricted to 
probes present on the HT12v3 array. I found that 50% (367 among 734) of cis-eQTLs in hippocampal 
brain tissue matched to the cis-eQTLs in blood cells detected by Schramm et al. (2014), and 58% (423 
among 734) matched with those reported by Westra et al. (2013). Altogether, some cross-tissue 
similarities within cis-eQTLs from hippocampal brain tissue and whole blood cells were observed. 
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These offer the option to delineate accessible transcriptomic biomarkers for at least some eQTLs 
observed in brain. 
 
4.5 Autosomal map of trans-eQTLs in human hippocampal brain tissue 
Altogether, 16 trans-eQTLs with a low significance level were observed of which none has been 
previously reported (cf. Gibbs et al. 2010; Westra et al. 2013; Ramasamy et al. 2014; Schramm et al. 
2014). The available sample size seems to be too small to detect larger effect sizes of trans-eQTLs –
 this is consistent with general trends in the literature. Westra and Franke (2014) reported that effect 
sizes of trans-eQTLs are generally small in contrast to cis-eQTL effects. 
 
4.6 Delineation of methylation-driven gene expression in hippocampal brain 
tissue 
Correlation analysis of CpG methylation with mRNA gene expression revealed both inverse and 
positive correlations. Overall, 73% of CpG-mRNA pairs were inversely correlated and showed an 
enrichment of methylated CpG sites at active promoters in combination with a reduced gene 
expression. This is in congruence with previous studies, which demonstrated that DNA methylation 
at promoter regions reduces gene expression levels (Jones 2012; Gutierrez-Arcelus et al. 2013). 
Furthermore, results also show that CpG-mRNA pairs with inverse correlation were frequently 
associated with methylated CpG sites at strong enhancers. Additionally, the observed results suggest 
that CpG sites affecting gene expression are more likely enriched in non-CpG island (CGI) regions 
than within CGIs (P < 2.2 x 10-16). CpG sites within CGIs were predominately unmethylated and do not 
substantially contribute to the variance of gene expression. When analyzing CpG-mRNA pairs for 
which the target methylation site resided within a CGI, the classical inverse relationship of increased 
CpG methylation associated with decreased expression levels was observed (in 71% of these cases). 
There are only few studies reporting that DNA methylation was positively correlated with gene 
expression levels (Gibbs et al. 2010; Bell et al. 2011; Gutierrez-Arcelus et al. 2013; Banovich et al. 
2014). Previous studies demonstrated that DNA methylation in gene bodies is often associated with 
activating histone mark and increased expression levels (Hahn et al. 2011; Jones 2012). In contrast, I 
did not observe a difference in the direction of correlations between CpG sites within or outside gene 
bodies. Instead, it was found that the CpG and transcription start site (TSS) tend to be more distant 
from each other in positive correlated CpG-mRNA pairs. This finding was evident with the observed 
depletion at active promoters and in the TSS200 region for the positive correlated CpG-mRNA pairs. 
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Exploring the functional effects of SNPs on both DNA methylation and gene expression, only 44 
genes were identified fitting this constellation. There may be several explanations for this, including 
that i) the coverage of the HT12v3 expression array is limited, ii) gene expression levels are 
controlled by many other factors such as TF binding, chromatin state including histone marks and 
nucleosome positioning, and by regulation of small RNAs, and iii) the sample size of brain tissue of 
115 mTLE patients only provided modest power for eQTL and meQTL mapping. However, compared 
to the four existing studies which correlated CpG methylation to mRNA gene expression in 
postmortem brain tissue (Gibbs et al. 2010; Zhang et al. 2010; Gamazon et al. 2013; Numata et al. 
2014), the present study revels more CpG methylation and gene expression correlations whereby the 
CpG methylation and the mRNA expression was significant genetically determined. This is due to the 
superior genomic coverage of CpG sites investigated by the HM450 array compared to the HM27 
array employed by the reference studies. 
4.6.1 Functional implications of meQTL and eQTL effects on NAPRT1 expression 
An example of the translational impact of the epigenetic regulation of gene expression is illustrated 
by using meQTL and eQTL findings on the NAPRT1 gene, which encodes Nicotinate 
Phosphoribosyltransferase. I was able to demonstrate that the strong inverse correlations of seven 
CpGs in the promoter region of NAPRT1 (correlation coefficient range = -0.83 to -0.72) were 
genetically determined and controlled via a common rSNP.  
In detail, the correlation analysis revealed that five of the seven CpGs reside in a CpG island 
(chr8:144,659,745-144,660,635; assigned as CpG: 94) and overlap with the TSS of NAPRT1. 
Furthermore, the present meQTL and eQTL results suggest that methylation-driven gene expression 
of NAPRT1 is modulated by the genotype of SNP rs9657360 or a nearby rSNP in strong LD with the 
screening SNP. The minor C-allele (MAF(C)-EUR: 0.20) of the common meQTL/eQTL lead SNP 
rs9657360 is significantly associated with high methylation state level of the CpG: 94 island in the 
NAPRT1 promoter region and low gene expression of NAPRT1. Both, the tumor-specific 
hypermethylation of the promoter CpG: 94 island as well as loss of NAPRT1 expression has been 
previously proposed as predictive biomarkers for the therapy of carcinomas using NAMPT inhibitors 
(Shames et al. 2013; Sampath et al. 2015). Considering that a low expression level of NAPRT1 
increases the therapeutic index of NAMPT inhibitors in cancer, approximately 4% of the general 
population carrying a homozygous C/C genotype of SNP rs9657360 should be responsive for NAMPT 
inhibitors. Thus, this genetic risk constellation is of clinical relevance as it enables a diagnostically 
driven clinical strategy in tumorigenesis including the selection of patients which likely benefit from 
the administration of NAMPT inhibitors (Shames et al. 2013; Sampath et al. 2015). 
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4.7 Dissection of rSNPs involved in common neuropsychiatric disorders 
It was aimed to identify causative rSNPs, which increase the risk of common neuropsychiatric 
disorders. Previous studies have demonstrated that transcription factor binding sites (TFBSs) 
influence DNA methylation and gene expression (Stadler et al. 2011; Ziller et al. 2013; Tsankov et al. 
2015). To decipher the role of potential rSNPs in neuropsychiatric disorders, it was examined 
whether SNPs in strong LD (r2 > 0.8) with the GWAS lead SNPs and nearby cis-QTLs cause allelic 
alterations of TFBSs and change the binding affinity of TFs. Two examples are highlighted below. 
The first example involves a GWAS susceptibility locus on chromosome 1q31.2 (RGS1 gene locus) that 
has been associated with the risk of multiple sclerosis (MS; Sawcer with the International Multiple 
Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 2011). MS is a 
chronic inflammatory demyelinating disease of the central nervous system (CNS). All cis-meQTL SNPs 
in high LD (r2 > 0.8) with the GWAS lead SNP rs1323292 were also significantly associated with 
meQTL-CpG cg02586212 (N = 17, P < 2.4 x 10-14). The most promising LD SNP rs2760528 (CADD 6.8) 
resides in an evolutionarily conserved sequence (GERP++ score: 3.33) and causes an alteration of the 
binding affinity of five closely related TRANSFAC binding motifs of the TF STAT (Signal Transducer and 
Activator of Transcription, Figure 4-1). The strongest allelic alteration of the STAT binding affinities 
was found for the STAT3 (P-value = 4.93 x 10-5) and the STAT5A (P-value = 5.74 x 10-5) TFBS. STAT 
family proteins are major regulators of general immune response mediated by the interplay of STAT 
family proteins with diverse interleukines (IL) and other cytokines regulating T-cell differentiation 
(Adamson et al. 2009). An abnormal humoral immune response has been described in MS patients 
(Hafler et al. 2005). The strong LD of SNP rs2760528 with the MS GWAS lead SNP rs1323292 
(distance = 4.2 kb; LD = 0.99) implicates a potential functional role of the gene RGS1, encoding the 
regulator of G-protein signaling 1. Previous studies provided evidence for an involvement of RGS1 in 
the pathogenesis of MS (International Multiple Sclerosis Genetics Consortium 2010; Tran et al. 2010) 
and Sawcer and co-workers (2011) identified for the first time RGS1 as candidate gene for MS via a 
GWAS. It has been shown that RGS1 is expressed in immune cells and that overexpression in B-cells 
attenuates chemokine signaling which plays a major role in attracting immune cells to the site of 
inflammation (Moratz et al. 2004). An upregulation of RGS1 measured by gene expression profiling in 
MS patients highlights the possible importance of RGS1 for the regulation of chemokine activity in 
the treatment of MS (Tran et al. 2010). Alterations of RGS1 expression, potentially through an allelic 
alteration of the binding affinity of the TFs STAT3/STAT5, could impair the migratory capability of B-
cells and possibly alter their migration into the CNS (International Multiple Sclerosis Genetics 
Consortium 2010). Well fitting, several reports provide evidence for a role of B-cells in the 
immunopathology of MS (Lucchinetti et al. 2000; Cross et al. 2001; Hafler et al. 2005). 
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Figure 4-1: Chromosome 1q31.2 region. 
The GWAS lead SNP rs1323292 associated with the risk of MS is illustrated and highlighted in red, as well as the cis-meQTL 
CpG cg02586212. The LD SNP rs2760528 is highlighted in blue. Further, regulatory elements such as DNaseI Hypersensitive 
sites, genome segmentations and conserved TFBS for the chromosome 1q31.2 region are shown. 
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The second example involves a GWAS locus on chromosome 3p21.1 (gene complex 
NEK4/PRBM1/ITIH3/GNL3) that is associated with the risk of several neuropsychiatric disorders 
including bipolar disorder and major depressive disorder (McMahon et al. 2010), autism spectrum 
disorder and schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013). All 
cis-meQTL SNPs in high LD (r2 > 0.8) with the GWAS lead SNP rs2251219 (PRBM1) for major mood 
disorder on chromosome 3 were also significantly associated with the meQTL CpG cg18099408 
(N = 216, P < 6.6 x 10-11). The cis-meQTL SNP rs2251219 was prioritized as top-ranking variant 
because the synonymous SNP rs2251219 in the PRBM1 gene affects many regulatory elements 
including two active enhancer marks (H3K27ac and H3K4me1), resides in an evolutionarily conserved 
sequence (GERP++ score: 3.54), and encompasses binding sites for four TFs (TRANSFAC binding 
motifs). The strongest TFBS affinity was obtained for the Tal1 motif (P-value = 4.28 x 10-3) which is 
involved in the differentiating of midbrain and hindbrain GABAergic neurons (Achim et al. 2012; 
Achim et al. 2013). The GWAS lead SNP rs2251219 displays a CADD score of 9 indicating that this 
potential rSNP is ranked among the 10% most deleterious substitutions in the human genome. The 
GWAS lead SNP rs2251219 is located in PRBM1, which encodes polybromo-1 and is important in 
chromatin remodeling (Thompson 2009). McMahon and co-workers (2010) demonstrated that 
PRBM1 is overexpressed in the dorsolateral prefrontal cortex of patients with bipolar disorder. The 
cis-regulation of gene PRBM1 could take place potentially through an allelic alteration of the binding 
affinity of the Tal1 TFBS. Additionally, cis-eQTLs of SNP rs2251219 have been reported with mRNA 
expression of ITIH4, GLT8D1, NT5DC2, PRBM1 and STAB1 (Xia et al. 2012; Witt et al. 2014). Witt and 
colleagues (2014) emphasized STAB1 as a new and highly promising candidate gene for bipolar 
disorder in the chromosome 3p21.1 region based on gene-expression studies in postmortem tissue 
of the dorsolateral prefrontal cortex which revealed differential expression of STAB1 in bipolar 
disorder and schizophrenia patients compared with controls. STAB1 encodes a multifunctional 
scavenger receptor, and its expression is induced during chronic inflammation and tumor progression 
(Kzhyshkowska 2010). STAB1 is located in close proximity to gene PRBM1 (distance = 21 kb). The 
strong LD across the chromosomal ITIH4/GLT8D1/NT5DC2/PRBM1/STAB1 segment (r2 > 0.9) hinders 
the efforts to dissect rSNPs of single target genes for neuropsychiatric disorders (McMahon et al. 
2010). Complementarily, deleterious non-synonymous SNPs affecting the protein structure facilitate 
the identification of underlying disease genes. The non-synonymous SNP variant rs4434138 
(p.I2282V), located in the STAB1 gene, is in high LD (r2 > 0.78) with the GWAS lead SNP rs2251219 
and display a high CADD score of 11.3, supporting STAB1 as promising target gene for 
neuropsychiatric disorders, especially bipolar disorder. Noteworthy, additional non-synonymous LD 
SNPs associated with meQTLs in the 3p21.1 GWAS candidate region, display high CADD and GERP++ 
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scores and could be considered as potential susceptibility variants (e.g. SNP rs1029871, NEK4 
p.P225A, CADD 29.2, GERP++ 5.9; SNP rs678, ITIH1 p.E585V, CADD 17.2, GERP++ 5.3).  
My explorations highlight several potential rSNPs within the GWAS candidate loci on chromosome 
1q31.2 (RGS1 gene locus) and 3p21.1 (PRBM1 gene locus) based on their allelic alteration of TFBSs, 
strong enhancer marks, DNaseI-hypersensitive sites and gene expression. The allelic alteration of 
TFBSs by potential rSNPs is likely to result in changes of the binding affinities of TFs and thereby gene 
transcription or splicing processes. Notably, rSNPs extend the allelic spectrum of disease genes and 
may explain a substantial fraction of the missing heritability. 
 
4.8 Outlook 
The rapidly growing number of catalogs of QTLs provides deeper insights into the functional impact 
of regulatory variation and epigenetic processes in neuropsychiatric disorders (Westra & Franke 
2014; Albert & Kruglyak 2015; Januar et al. 2015; Kundaje et al. 2015). The Roadmap Epigenetics 
Project of the US National Institute of Health has generated the most comprehensive human 
epigenomic landscape across the largest collection of primary cells and tissues (Kundaje et al. 2015), 
which provides the key to integrate genomic variability with regulatory processes in a spatial and 
temporal context. However, our understanding of the exact mechanisms by which epigenetic 
changes modify phenotype is still very limited and further experimental work is necessary. 
Large sample sizes and tissue collections will be crucial to ensure that no relevant QTLs will be 
missed, especially the trans-acting variants, whose effects are likely to be small. To find more trans-
QTLs, meta-analyses are required to scale up QTL studies. These meta-analyses will further provide a 
higher-resolution overview of the downstream effects of common and rare SNPs and will permit 
causal inference (Westra & Franke 2014). Larger tissue and cell-type specific data sets will specify the 
cell-type specific QTL effects. To address this need, the Roadmap Epigenomics Consortium has linked 
epigenomic data to genetic information and produced reference epigenomes for 127 tissue and cell-
types (Kundaje et al. 2015; Romanoski et al. 2015). It is important to generate QTL maps under a 
variety of physiologically important conditions to ensure that the relevant biology is captured (Albert 
& Kruglyak 2015). The examination of changes in the disease over time and longitudinal epigenetic 
data at various points in time is crucial. The optimum would involve a longitudinal study of disease-
associated tissue of patients collected prior to disease onset and followed up at multiple times 
throughout the course of the disease. A number of such studies are currently in progress (Pembrey et 
al. 2014).  
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The connections along the causal chain from DNA variant to altered expression and trait variation is 
complex and the identification of large catalogs of causal variants that underlie meQTLs or eQTLs still 
remains a major challenge (Albert & Kruglyak 2015). To maximize the chance to link GWAS hits with 
intermediate QTLs, it is necessary to map QTLs in disease-associated tissues (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium 2014; Torres et al. 2014). Currently, all QTL studies 
focusing on common brain disorder used postmortem brain tissue (cf. Table 6-2) to measure 
methylation and expression levels what entails several limitations. Fresh frozen hippocampal brain 
tissue would be the first choice to perform QTL analyses to study neuropsychiatric disorders. 
Alternatively, if tissues are difficult to obtain or if they represent complex mixtures of cell-types, such 
as brain tissues, differentiated induced pluripotent stem (iPSC) cells provide a promising option 
(Sterneckert et al. 2014). In addition, to prioritize putative causal links between DNA variation, 
expression and phenotypes further development of advanced data integration will be required. 
Another important factor arises from the recent and rather rapid advances in technology, which 
ultimately enabled the acquisition of huge epigenomic data. NGS and microarray technology now 
offer an option for automated high-throughput data generation and allow mapping of DNA 
methylation at a high genome-wide resolution and in a large number of samples (Laird 2010). The 
HM450 array is the most popular platform to profile DNA methylation. However, the platform does 
not differentiate between methylation and 5-Hydroxymethylcytosine (5hmC). This seems to be a 
limitation as 5hmC appears to be abundant in brain tissue (Szulwach et al. 2011; Lister et al. 2013) 
and has recently been discovered to play a critical role in dynamic regulation of genes silenced by 
methylation (Bhutani et al. 2011; Numata et al. 2012). Furthermore, 5hmC has been implicated in 
neurodevelopment and could be particularly important in neuropsychiatric disorders (Tseng et al. 
2014). Recent studies hypothesize that positive correlation between CpG methylation and gene 
expression levels is due to 5hmC as it has been shown that 5hmC has activating effects on 
transcription (Yu et al. 2012; Banovich et al. 2014). Histone acetylation and chromatin marks are 
other epigenetic modifications, which seem to play an important role in the regulation of gene 
expression. Histone mark combinations show distinct levels of DNA methylation and predict 
differences in RNA expression levels that are not reflected in DNA methylation (Kundaje et al. 2015). 
ChIP-Seq studies permit the targeting of pertinent transcription factors that regulate gene expression 
within susceptibility loci (Bennett et al. 2015). All these results will inform the identification and 
refinement of molecular networks that can lead to neuropsychiatric disorders and are influenced by 
their pathology. 
Most published eQTL mapping studies have measured gene expression levels using microarray 
technology (Westra & Franke 2014) and there are also several eQTL studies available which used the 
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HT12v3 array (Schurmann et al. 2012; Westra et al. 2013; Schramm et al. 2014). However, the 
HT13v3 array has been designed to measure whole gene expression and has limitations to 
differentiate gene isoforms (Pickrell et al. 2010). Recent advances in RNA sequencing (RNAseq) 
enable the relatively unbiased measurements of expression levels across the entire length of a 
transcript (Wang et al. 2009). RNAseq comprehensively covers of the entire transcriptome including 
transcript isoforms, splicing aberrations and RNA-editing modifications (Liang et al. 2013). In 
addition, RNAseq offers a higher resolution of gene expression quantification than microarrays 
(Westra & Franke 2014) and allows better mapping of cis-eQTLs within exons (Montgomery et al. 
2010; Westra & Franke 2014). 
Considering the high complexity of the brain and neuropsychiatric disorders including epilepsy, 
autism spectrum disorder, bipolar disorder and schizophrenia, integrative functional genomic studies 
improve the prospects to dissect the complex gene regulation processes in human brain disorders. 
My study has integrated high-density data sets of SNPs, CpG methylation and gene expression on a 
genome wide level from the unique resource of fresh frozen human epileptic brain tissue. It was 
demonstrated that methylation as well as expression levels are affected by genetic variation at a 
large number of loci across the genome. The presented results provide an initial basis for 
understanding how genetic variance in humans influences epigenetic marks and expression and 
forms the basis for further comprehensive analyses.  
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6. APPENDIX 
6.1 Clinical parameters of 115 mTLE patients 
Parameters including gender, pathology and drug therapy are presented in percentage values. Age at 
epilepsy surgery in years and age at seizure onset in years are presented in mean ± SEM values. 
Biopsy specimens were analyzed according to international standards and the diagnostic 
classification was established by an experienced neuropathologist according to international criteria 
(Becker et al. 2003; Blumcke et al. 2007). The hippocampi were stratified according to the 
pathological pattern of the patient into two groups: Ammon’s horn sclerosis (segmental neuronal cell 
loss and concomitant astrogliosis and microglia activation) and lesion associated (cortical dysplasia or 
tumors). 
Table 6-1: Distribution of clinical parameters within sample group. 
Number of mTLE patients 
Gender (male vs. female) 
Age at seizure onset in years 
Drug therapy (Sodium-channel blockers monotherapy vs. levetiracetam 
combinations vs. non-levetiracetam combinations) 
Age at epilepsy surgery in years 
Pathology (Ammon’s horn sclerosis vs. lesion associated) 
115 
52.2% vs. 47.8% 
11.1 ± 8.7 
19.1% vs. 36.6% vs. 44.3% 
 
31.5 ± 14.2 
68.7% vs. 31.3% 
 
6.2 Confirmation analyses of cis-meQTLs and cis-eQTLs in hippocampal brain 
tissue and whole blood cells 
In recent years, most meQTL studies which assess methylation levels of postmortem brain tissue and 
whole peripheral blood cells used the Infinium Human Methylation27 BeadChip (HM27; Gibbs et al. 
2010; Zhang et al. 2010; Numata et al. 2012; Gamazon et al. 2013; Smith et al. 2014; Numata et al. 
2014), while only few used the HM450 array in different blood cell lines (Gutierrez-Arcelus et al. 
2013; Banovich et al. 2014). 
eQTL studies which assess expression levels of postmortem brain tissue use different arrays to profile 
mRNA transcript in comparison with my analysis (Gibbs et al. 2010; Gamazon et al. 2013; Ramasamy 
et al. 2014; Kim et al. 2014). As confirmation criteria the significant cis-eQTL SNPs from the four 
studies had to be within 1 Mbps of the mRNA transcription site. Additionally, the SNPs had to be in 
LD of r2 > 0.2 with my cis-eQTL SNPs. An eQTL analysis in whole blood cell samples was performed 
using also the Illumina HumanHT-12 v3 (HT12v3) expression BeadChip (Schramm et al. 2014) and a 
meta-eQTL analysis in whole blood cells was performed by restricting their analysis to sequences 
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present on the HT12v3 platform (Westra et al. 2013). The previous meQTL and eQTL studies are 
described in Table 6-2. 
  
 
Table 6-2: Reference meQTL and eQTL studies exploited for confirmation analyses. 
Epigenetic 
study 
Reference Statistics Array type Tissue-/Cell-type Number of individuals 
in QTL analyses 
Phenotypic trait* 
Methylation Banovich et al. 2014 cis-meQTL HM450 Blood, LCLs 64 
none specific 
phenotypic trait 
Methylation Smith et al. 2014 cis-meQTL HM27 
Whole blood & 4 brain 
regions, postmortem 
(CRBLM, FCTX, PONS, TCTX)  
90 (blood), 105 
(CRBLM), 111 (FCTX), 
106 (PONS), 125 (TCTX) 
none specific 
phenotypic trait 
Methylation Numata et al. 2012 cis- & trans-meQTL HM27 Brain, postmortem (PFC) 108 
none specific 
phenotypic trait 
Methylation 
& Expression 
Numata et al. 2014 
cis-meQTL, correlation 
methylation/expression 
HM27 & IL Human HT-
12 v3 
a
 
Brain, postmortem (DLPFC) 
216 (106 with 
schizophrenia, 110 non-
psychiatric controls) 
Schizophrenia 
Methylation 
& Expression 
Gamazon et al. 2013 
cis-meQTL & cis-eQTL, 
correlation 
methylation/expression 
HM27 & Affy Human 
Gene 1.0 ST 
Brain, postmortem (CRBLM) 
153 (132 for correlation 
analysis) 
Bipolar disorder 
Methylation 
& Expression 
Gutierrez-Arcelus et 
al. 2013 
cis- meQTL & cis-eQTL, 
correlation 
methylation/expression 
HM450 & RNAseq 
Blood, fibroblasts, LCLs, T-
cells 
107-183 (fibroblasts), 
11-185 (LCLs), 66-186 
(T-cells) 
none specific 
phenotypic trait 
Methylation 
& Expression 
Bell et al. 2011 
cis- & trans meQTL, 
correlation 
methylation/expression 
HM27 & RNAseq 
b
 Blood, LCLs 
77 (69 for correlation 
analysis) 
none specific 
phenotypic trait 
Methylation 
& Expression 
Zhang et al. 2010 
cis- & trans meQTL, 
correlation 
methylation/expression 
HM27 & Affy 
HGU95Av2 
c
 
Brain, postmortem (CRBLM) 
153 (45 for correlation 
analysis) 
none specific 
phenotypic trait 
Methylation 
& Expression 
Gibbs et al. 2010 
cis- & trans-meQTL, cis- & 
trans-eQTL, correlation 
methylation/expression 
HM27 & IL HumanRef-8 
Brain, 4 regions, postmortem 
(CRBLM, FCTX, PONS, TCTX) 
150 (from each human 
brain region) 
none specific 
phenotypic trait 
Expression Ramasamy et al. 2014 cis- & trans-eQTL Human exon 1.0 ST 
Brain, 10 regions, 
postmortem 
d
 
134 
Parkinson’s disease 
and other brain 
disorders 
Expression Kim et al. 2014 
Meta-analysis (5 studies), 
cis-eQTL 
RNAseq, IL Human 49k 
oligo, IL HumanRef-8 v2, 
Affy HG-U133a 
Brain, postmortem (FCTX, 
TCTX) 
424 (235 in FCTX, 189 in 
FCTX 6 TCTX) 
Psychiatric disorders 
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Table 6-2 (continued): Reference meQTL and eQTL studies exploited for confirmation analyses.  
Epigenetic 
study 
Reference Statistics Array type Tissue-/Cell-type Number of individuals Phenotypic trait* 
Expression Schramm et al. 2014 cis- & trans eQTL  IL Human HT-12 v3 Whole Blood 890 
Immune response & 
metabolic traits 
Expression Westra et al. 2013
 e
 
Meta-analysis (7 studies), 
cis- & trans-eQTL 
IL Human HT-12 v3, IL 
Human HT-12 v4, IL 
HumanRef-8 v2 
Whole Blood 5,311 
Type 1 diabetes & 
cholesterol 
metabolism 
Abbreviations: eQTL, expression quantitative trait loci; meQTL, methylation quantitative trait loci; HM27, Illumina Human Methylation27k BeadChip; HM450, Illumina Human Methylation450k 
BeadChip; IL, Illumina; Affy, Affymetrix; RNA seq, RNA sequencing; CRBLM, cerebellum; DLPFC, dorsolateral prefrontal cortex; FCTX, frontal cortex; PFC, prefrontal cortex; PONS, caudal pons; TCTX, 
temporal cortex; LCL, lymphoblastoid cell line. *Selections of traits from those highlighted in the given paper are shown; meQTLs and eQTLs are often compared to many more traits. 
a
 Numata et 
al. (2014) utilized previously published expression data from the DLPFC obtained using HumanHT-12_V3 Illumina BeadArrays as described in detail in Ye et al. (2012). 
b
 Bell et al. (2011) used the 
RNA-sequencing data which were obtained for LCLs from 69 individuals in the study from Pickrell et al. (2010). 
c
 Zhang et al. (2010) used expression data from cerebellum for 45 of the same 
individuals, available from the SMRI Online Genomics Database. 
d
 The ten human brain regions from Ramasamy et al. (2014) included cerebellar cortex (CRBL), frontal cortex (FCTX), hippocampus 
(HIPP), inferior olivary nucleus (sub-dissected from the medulla, MEDU), occipital cortex (OCTX), putamen (PUTM), substantia nigra (SNIG), temporal cortex (TCTX), thalamus (THAL), intralobular 
white matter (WHMT). 
e
 Westra et al. (2013) represents the largest eQTL meta-analysis so far. 
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6.3 Master regulatory loci of trans-meQTL SNPs 
Table 6-3: Master regulatory sites – trans-meQTL SNPs with simultaneous impact on the methylation of at least four genes. 
SNP Chr SNP SNP Pos Gene of SNP CpG Chr CpG CpG Pos Gene of CpG FDR 
rs12137847 1 218227046 RP11-152L7.1(20.0k) cg27508046 12 124249428 DNAH10 1.78E-03 
 1 218227046 RP11-152L7.1(20.0k) cg17892401 7 32529540 LSM5 1.16E-02 
 1 218227046 RP11-152L7.1(20.0k) cg03026929 6 32806028 TAP2 3.48E-02 
 1 218227046 RP11-152L7.1(20.0k) cg22684443 3 169756200 GPR160 4.90E-02 
rs12464646 2 45339491 NA cg09603795 10 75256221 RP11-137L10.6 2.87E-02 
 2 45339491 NA cg07805911 7 818287 HEATR2 3.74E-02 
 2 45339491 NA cg11637718 16 4029254 ADCY9 3.98E-02 
 2 45339491 NA cg00299396 11 115483607 AP000997.1(15.2k) 4.43E-02 
 2 45339491 NA cg05262711 16 2807476 SRRM2 4.92E-02 
rs73944570 2 104844126 NA cg14061772 12 73266969 AC131213.1(82.5k) 3.01E-03 
 2 104844126 NA cg20701799 3 10549576 ATP2B2 1.23E-02 
 2 104844126 NA cg22538778 12 63294404 PPM1H 4.22E-02 
 2 104844126 NA cg14047244 19 2457194 GADD45B(18.9k) 4.40E-02 
rs114267096 6 31572801 AIF1(10.2k) cg26221494 8 575388 ERICH1 5.10E-03 
 6 31572801 AIF1(10.2k) cg20814026 2 71205520 AC007040.11 1.32E-02 
 6 31572801 AIF1(10.2k) cg21685048 2 17771856 VSNL1 2.93E-02 
 6 31572801 AIF1(10.2k) cg14720996 3 130278864 COL6A6(0.3k) 4.78E-02 
rs59758536 7 83391843 NA cg12615916 1 227505854 CDC42BPA 5.03E-04 
 7 83391843 NA cg10519543 7 47694732 C7orf65(0.1k) 1.83E-03 
 7 83391843 NA cg13642142 9 139572213 AGPAT2 4.59E-03 
 7 83391843 NA cg04512931 17 43341971 MAP3K14 2.49E-02 
 7 83391843 NA cg19600667 4 6030497 JAKMIP1 4.80E-02 
 7 83391843 NA cg17013990 1 161091682 DEDD 4.94E-02 
rs3920533 11 32297640 NA cg24870476 1 221910211 DUSP10 3.14E-04 
 11 32297640 NA cg18496271 19 1388932 NDUFS7 2.29E-02 
9
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Table 6-3 (continued): Master regulatory sites – trans-meQTL SNPs with simultaneous impact on the methylation of at least four genes. 
SNP Chr SNP SNP Pos Gene of SNP CpG Chr CpG CpG Pos Gene of CpG FDR 
 11 32297640 NA cg11931953 7 4781767 FOXK1 4.44E-02 
 11 32297640 NA cg03906031 11 72489173 ARAP1 4.52E-02 
rs1273196 14 64739505 SYNE2(46.3k) cg08822494 15 88279757 RP11-648K4.2(32.7k) 9.61E-04 
 14 64739505 SYNE2(46.3k) cg01845013 14 80697777 DIO2-AS1 1.18E-02 
 14 64739505 SYNE2(46.3k) cg18450582 7 95546539 DYNC1I1 1.71E-02 
 14 64739505 SYNE2(46.3k) cg26714129 8 142310710 SLC45A4 2.27E-02 
 14 64739505 SYNE2(46.3k) cg11377054 13 112189885 RP11-65D24.2(50.7k) 2.30E-02 
 14 64739505 SYNE2(46.3k) cg21484956 12 77273469 RP11-461F16.3 2.46E-02 
chr19:40667344:D 19 40667344 MAP3K10(30.3k) cg08008562 1 154530682 UBE2Q1 3.02E-02 
 19 40667344 MAP3K10(30.3k) cg04322363 3 159757071 CTD-2049J23.2 4.39E-02 
 19 40667344 MAP3K10(30.3k) cg10487970 2 63277030 OTX1(0.2k) 4.46E-02 
 19 40667344 MAP3K10(30.3k) cg22539294 3 167033938 ZBBX 4.57E-02 
Abbreviations: SNP, SNP of the significant trans-meQTLs in hippocampal brain tissue; Chr SNP, chromosome of the respective SNP; SNP Pos, base-pair position of SNP in hippocampal brain tissue; 
Gene of SNP, gene which contains the SNP site; CpG, Illumina annotation of the CpG dinucleotide; Chr CpG, chromosome of the respective CpG; CpG Pos, cytosine base-pair position of CpG site; 
Gene of CpG, gene which contains the CpG site; FDR, significant FDR for a SNP-CpG pair in hippocampal brain tissue samples. All annotations refer to genome build hg19. 
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6.4 QQ-plots of QTL analyses 
6.4.1 QQ-plots of meQTL analysis 
 
Figure 6-1: QQ-plot of CpG methylation in 115 hippocampal brain tissue samples and 496 blood cell samples. 
QQ-plots in 115 hippocampal brain tissue samples (left side) and 496 blood cell samples (right side). Distribution of cis-
meQTLs (± 1 Mbps) is in red; distribution of trans-meQTLs is in blue. 
 
6.4.2 QQ-plots of imeQTL analysis 
 
Figure 6-2: QQ-plot of CpG methylation in 269 parent-offspring trios (heterozygote test). 
QQ-plots in 269 parent-offspring trios of the imeQTL heterozygote test. Distribution of cis-imeQTLs (± 1 Mbps) is in red; 
distribution of trans-imeQTLs is in blue. 
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Figure 6-3: QQ-plot of CpG methylation in 269 parent-offspring trios (maternal and paternal imeQTL analysis). 
QQ-plots in 269 parent-offspring trios of the maternal imeQTL analysis (left side) and the paternal imeQTL analysis (right 
side). Distribution of cis-imeQTLs (± 1 Mbps) is in red; distribution of trans-imeQTLs is in blue. 
 
6.4.3 QQ-plot of eQTL analysis 
 
Figure 6-4: QQ-plot of mRNA expression in 115 hippocampal brain tissue samples. 
Distribution of cis-eQTLs (± 1 Mbps) is in red; distribution of trans-eQTLs is in blue. 
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